Chemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHealth CareGeographicals
Investigational New Drug ApplicationDrugs, InvestigationalUnited States Food and Drug AdministrationDrug ApprovalLegislation, DrugDrugs, GenericDrug LabelingPatents as TopicClinical Trials as TopicUnited StatesTherapeutic EquivalencyClinical Trials, Phase I as Topic
Investigational New Drug Application
An application that must be submitted to a regulatory agency (the FDA in the United States) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (From the "New Medicines in Development" Series produced by the Pharmaceutical Manufacturers Association and published irregularly.)
Drugs, Investigational
Drugs which have received FDA approval for human testing but have yet to be approved for commercial marketing. This includes drugs used for treatment while they still are undergoing clinical trials (Treatment IND). The main heading includes drugs under investigation in foreign countries.
United States Food and Drug Administration
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
Drug Approval
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
Legislation, Drug
Laws concerned with manufacturing, dispensing, and marketing of drugs.
Drugs, Generic
Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies.
Drug Labeling
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
Patents as Topic
Exclusive legal rights or privileges applied to inventions, plants, etc.
Clinical Trials as Topic
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
United States
Therapeutic Equivalency
The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.
Clinical Trials, Phase I as Topic
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.

Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example. (1/34)

The following material was derived from a synthesis of case histories taken from investigational new drug (IND) applications and drug sponsors' experiences, utilizing fictionalized data to avoid any resemblance to any proprietary information; any such resemblance is accidental. These examples are used as an instructional scenario to illustrate appropriate handling of a difficult toxicology issue. In this scenario, a drug caused a toxicity in animals that was detected only by histopathologic analysis; if it were to develop in patients, no conventional clinical methods could be identified to monitor for it. It is not unusual for a firm to cancel clinical development plans for a lead drug candidate that causes such a toxicity, especially if such a drug is intended for use as a chronic therapeutic in a population of patients with a chronic disease. This case synthesis was inspired by a Food and Drug Administration (FDA) agreement to allow such a product to proceed into clinical trials after substantive pre-IND discussions and agreement on well-considered toxicology program designs. The scientists most closely involved in the strategy development included the sponsor's toxicologist, veterinary toxicologic pathologist, and pharmacokineticist, as well as the FDA's reviewing pharmacologist. The basis of this decision was thorough toxicity characterization (1-month studies in 2 species); correlating toxicities with a particular cumulative area under the curve (AUC) in both species; identification of the most sensitive species (the species that showed the lower AUC correlating with toxicity); allometric assessment of clearance of the drug in 3 nonhuman species; construction of a model of human kinetics (based on extrapolation from animal kinetics); and finally, estimation of clinical safety factors (ratios of the human estimated cumulative AUC at the proposed clinical doses, over the animal cumulative AUC that correlated with the no adverse effect levels). Industry and FDA scientists negotiated a joint assessment of risk and benefit in patients, resulting in the FDA permitting such a compound to enter into clinical trials for a serious autoimmune disease. Such constructive, early communication starts with the pre-IND meeting, and the conduct and planning for this meeting can be very important in establishing smooth scientific and regulatory groundwork for the future of a drug under IND investigation.  (+info)

Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. (2/34)

Many scientific discussions, especially in the past 8 yr, have focused on definition of criteria for the optimal assessment of the preclinical toxicity of pharmaceuticals. With the current overlap of responsibility among centers within the Food and Drug Administration (FDA), uniformity of testing standards, when appropriate, would be desirable. These discussions have extended beyond the boundaries of the FDA and have culminated in the acceptance of formalized, internationally recognized guidances. The work of the International Committee on Harmonisation (ICH) and the initiatives developed by the FDA are important because they (a) represent a consensus scientific opinion, (b) promote consistency, (c) improve the quality of the studies performed, (d) assist the public sector in determining what may be generally acceptable to prepare product development plans, and (e) provide guidance for the sponsors in the design of preclinical toxicity studies. Disadvantages associated with such initiatives include (a) the establishment of a historical database that is difficult to relinquish, (b) the promotion of a check-the-box approach, i.e., a tendancy to perform only the minimum evaluation required by the guidelines, (c) the creation of a disincentive for industry to develop and validate new models, and (d) the creation of state-of-the-art guidances that may not allow for appropriate evaluation of novel therapies. The introduction of biotechnology-derived pharmaceuticals for clinical use has often required the application of unique approaches to assessing their safety in preclinical studies. There is much diversity among these products, which include the gene and cellular therapies, monoclonal antibodies, human-derived recombinant regulatory proteins, blood products, and vaccines. For many of the biological therapies, there will be unique product issues that may require specific modifications to protocol design and may raise additional safety concerns (e.g., immunogenicity). Guidances concerning the design of preclinical studies for such therapies are generally based on the clinical indication. Risk versus benefit decisions are made with an understanding of the nature of the patient population, the severity of disease, and the availability of alternative therapies. Key components of protocol design for preclinical studies addressing the risks of these agents include (a) a safe starting dose in humans, (b) identification of potential target organs, (c) identification of clinical parameters that should be monitored in humans, and (d) identification of at-risk populations. One of the distinct aspects of the safety evaluation of biotechnology-derived pharmaceuticals is the use of relevant and often nontraditional species and the use of animal models of disease in preclinical safety evaluation. Extensive contributions were made by the Center for Biologics Evaluation and Research to the ICH document on the safety of biotherapeutics, which is intended to provide worldwide guidance for a framework approach to the design and review of preclinical programs. Rational, scientifically sound study design and early identification of the potential safety concerns that may be anticipated in the clinical trial can result in preclinical data that facilitate use of these novel therapies for use in humans without duplication of effort or the unnecessary use of animals.  (+info)

Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule. (3/34)

The Food and Drug Administration (FDA) is amending its regulations governing the format in which certain labeling is required to be submitted for review with new drug applications (NDAs), certain biological license applications (BLAs), abbreviated new drug applications (ANDAs), supplements, and annual reports. The final rule requires that certain labeling content be submitted electronically in a form that FDA can process, review, and archive. Submitting the content of labeling in electronic format will simplify the drug labeling review process and speed up the approval of labeling changes.  (+info)

Supplements and other changes to an approved application. Final rule. (4/34)

The Food and Drug Administration (FDA) is amending its regulations on supplements and other changes to an approved application to implement the manufacturing changes provision of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act). The final rule requires manufacturers to assess the effects of manufacturing changes on the identity, strength, quality, purity, and potency of a drug or biological product as those factors relate to the safety or effectiveness of the product. The final rule sets forth requirements for changes requiring supplement submission and approval before the distribution of the product made using the change, changes requiring supplement submission at least 30 days prior to the distribution of the product, changes requiring supplement submission at the time of distribution, and changes to be described in an annual report.  (+info)

Investigational new drugs: export requirements for unapproved new drug products. Final rule. (5/34)

The Food and Drug Administration (FDA) is amending its regulations on the exportation of investigational new drugs, including biological products. The final rule describes four different mechanisms for exporting an investigational new drug product. These provisions implement changes in FDA's export authority resulting from the FDA Export Reform and Enhancement Act of 1996 and also simplify the existing requirements for exports of investigational new drugs.  (+info)

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. (6/34)

The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression is often referred to as the pharmacometrics analyses. The objective of the current report is to assess the role of pharmacometrics at the US Food and Drug Administration (FDA) in making drug approval and labeling decisions. The New Drug Applications (NDAs) submitted between 2000 and 2004 to the Cardio-renal, Oncology, and Neuropharmacology drug products divisions were surveyed. For those NDA reviews that included a pharmacometrics consultation, the clinical pharmacology scientists ranked the impact on the regulatory decision(s). Of about a total of 244 NDAs, 42 included a pharmacometrics component. Review of NDAs involved independent, quantitative evaluation by FDA pharmacometricians, even when such analysis was not conducted by the sponsor. Pharmacometric analyses were pivotal in regulatory decision making in more than half of the 42 NDAs. Of the 14 reviews that were pivotal to approval related decisions, 5 identified the need for additional trials, whereas 6 reduced the burden of conducting additional trials. Collaboration among the FDA clinical pharmacology, medical, and statistical reviewers and effective communication with the sponsors was critical for the impact to occur. The survey and the case studies emphasize the need for early interaction between the FDA and sponsors to plan the development more efficiently by appreciating the regulatory expectations better.  (+info)

Current good manufacturing practice regulation and investigational new drugs. Direct final rule. (7/34)

The Food and Drug Administration (FDA) is amending its current good manufacturing practice (CGMP) regulations for human drugs, including biological products, to exempt most investigational "Phase 1" drugs from complying with the requirements in FDA's regulations. FDA will instead exercise oversight of production of these drugs under the agency's general statutory CGMP authority and investigational new drug application (IND) authority. In addition, FDA is making available simultaneously with the publication of this direct final rule, a guidance document setting forth recommendations on approaches to CGMP compliance for the exempted Phase 1 drugs. Elsewhere in this issue of the Federal Register, FDA is publishing a companion proposed rule, under FDA's usual procedure for notice-and-comment rulemaking, to provide a procedural framework to finalize the rule in the event the agency receives any significant adverse comments and withdraws this direct final rule. The companion proposed rule and direct final rule are substantively identical. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a draft guidance for industry entitled "INDs--Approaches to Complying With CGMP During Phase 1" to provide further guidance on the subject.  (+info)

The quantity and quality of worldwide new drug introductions, 1982-2003. (8/34)

We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately. Both biotech and orphan products enjoyed tremendous growth, especially for cancer treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch.  (+info)

VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma MultiformeVBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 15, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the companys Investigational New Drug Application (IND) for VBI-1901, a novel immunotherapy targeting Glioblastoma...
http://www.marketwired.com/press-release/vbi-vaccines-announces-fda-acceptance-investigational-new-drug-application-vbi-1901-nasdaq-vbiv-2230274.htm
Investigational New Drug Application Activated for GTX-102 for AngelmanInvestigational New Drug Application Activated for GTX-102 for Angelman
GTX-102 for Angelman syndrome is cleared for clinical trials following the FDAs activation of its investigational new drug application.
https://angelmansyndromenews.com/2020/01/28/investigational-new-drug-application-active-gtx-102-angelman-syndrome/
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for...BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for...
BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19 - read this article along with other careers information, tips and advice on BioSpace
https://www.biospace.com/article/releases/biosig-subsidiary-viralclear-submits-investigational-new-drug-application-to-the-fda-for-phase-ii-clinical-trials-for-merimepodib-an-orally-administered-treatment-for-patients-with-covid-19-/
Investigational New Drug application approved for LINCL treatmentInvestigational New Drug application approved for LINCL treatment
The FDA has granted Investigational New Drug application to PLX-200 to treat late infantile neuronal ceroid lipofuscinosis (LINCL).
https://www.europeanpharmaceuticalreview.com/news/111325/investigational-new-drug-application-approved-lincl-treatment/
Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy)...Ocugen Announces FDA Acceptance of Investigational New Drug Application for OCU310 (brimonidine/steroid combination therapy)...
Ocugen, Inc., a clinical stage biopharmaceutical company developing novel treatments for sight-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for OCU310 (brimonidine/steroid combination therapy), a topical formulation for the treatment of dry eye disease (DED). In addition, the Company announced that its first patient was dosed in a proof of concept study. This randomized, placebo-controlled, double-blind, multi-center, proof of concept study will assess the tolerability and preliminary efficacy of OCU310 for the treatment of DED.. We are very excited to begin our first clinical study and dose our first patient, said Daniel Jorgensen, MD, Chief Medical Officer at Ocugen. Our goal is to assess whether a combination product has potential benefit, in treating dry eye patients, while exploring the most appropriate endpoints for future pivotal studies.. This is an important milestone for Ocugen as we ...
http://ocugen.com/press-release/ocugen-announces-fda-acceptance-of-investigational-new-drug-application-for-ocu310-brimonidinesteroid-combination-therapy-and-initiates-proof-of-concept-study-for-treatment-of-dry-eye-disease/
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon(TM) TLR7/8 Agonist Clinical...Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon(TM) TLR7/8 Agonist Clinical...
COPENHAGEN, Denmark, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to create product candidates that address unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate the clinical program of TransCon TLR7/8 Agonist. TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8. Administered as an intratumoral injection, TransCon TLR7/8 Agonist is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor. The filing of our first oncology IND for TransCon TLR7/8 Agonist -- which is designed to provide intratumoral, sustained release of resiquimod over several weeks from a single administration with minimal systemic ...
https://www.barrons.com/press-release/ascendis-pharma-a-s-announces-filing-of-investigational-new-drug-application-to-initiate-transcon-tm-tlr7-8-agonist-clinical-program-01609362646?tesla=y&tesla=y
Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incytes epacadostat...Advaxis Announces FDA Clearance of Investigational New Drug Application for Phase 2 Study of ADXS-HPV and Incytes epacadostat...
... PRINCETON N.J. June 1 2015 /...In February 2015 Advaxis and Incyte entered into a non-exclusive clin... The FDA clearance of the ADXS-HPV plus epacadostat IND for HPV-associ...,Advaxis,Announces,FDA,Clearance,of,Investigational,New,Drug,Application,for,Phase,2,Study,of,ADXS-HPV,and,Incytes,epacadostat,for,the,Treatment,of,HPV-Associated,Early,Stage,Cervical,Cancer,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
http://www.bio-medicine.org/medicine-technology-1/Advaxis-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-Phase-2-Study-of-ADXS-HPV-and-Incytes-epacadostat-for-the-Treatment-of-HPV-45313-1/
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia | | IT Business Net
OXFORD, UK / ACCESSWIRE / March 13, 2019 / IntraBio Inc., a late-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA)
http://itbusinessnet.com/2019/03/intrabio-investigational-new-drug-application-approved-by-the-fda-for-the-treatment-of-ataxia-telangiectasia/
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the...CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the...
Certain statements set forth in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the timing of filing of clinical trial applications and INDs, the Companys ability to address questions raised by the regulators satisfactorily in connection with its clinical trial applications (CTAs) and INDs, the Companys ability to obtain regulatory approval(s) of its CTAs and/or its INDs, the timing of commencement of clinical trials, the intellectual property coverage and positions of the Company, its licensors and third parties, the sufficiency of the Companys cash resources and the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the Company believes that such statements are based on reasonable assumptions ...
http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-and-vertex-provide-update-fda-review
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001...
Certain statements set forth in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the timing of filing of clinical trial applications and INDs, any approvals thereof and timing of commencement of clinical trials, the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties, the sufficiency of CRISPR Therapeutics cash resources and the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of ...
https://www.ptcommunity.com/wire/crispr-therapeutics-and-vertex-announce-fda-has-lifted-clinical-hold-investigational-new-drug
Chimerix Announces Emergency Investigational New Drug Applications for Brincidofovir Authorized by FDA for Patients With Ebola...Chimerix Announces Emergency Investigational New Drug Applications for Brincidofovir Authorized by FDA for Patients With Ebola...
DURHAM, N.C., Oct. 6, 2014-- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that brincidofovir has been provided for potential use in patients with Ebola Virus Disease. Chimerix is committed to working with global health organizations and government agencies in the fight against...
https://www.cnbc.com/2014/10/06/globe-newswire-chimerix-announces-emergency-investigational-new-drug-applications-for-brincidofovir-authorized-by-fda-for-patients-with.html
Amgen Submits Biologics License Application for FDA Approval of PaliferminAmgen Submits Biologics License Application for FDA Approval of Palifermin
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 24, 2004--Amgen Inc. (Nasdaq:AMGN), the worlds largest biotechnology company, today announced submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for palifermin, a first-in-class investigational compound in development by Amgen for oral mucositis (mouth sores). The potential therapeutic indication is to reduce the incidence, duration and severity of oral mucositis in patients with hematologic malignancies undergoing high-dose chemotherapy, with or without irradiation, followed by a bone marrow transplant.. Approximately 11,000 Americans with hematologic malignancies, including non-Hodgkins lymphoma, Hodgkins disease, leukemia and multiple myeloma, undergo bone marrow transplants each year.. The BLA was submitted under the FDAs Fast Track designation program, which is designed to expedite FDA review of an investigational therapy for an unmet medical need. If approved, palifermin will be the first ...
http://www.amgen.com/media/news-releases/2004/06/amgen-submits-biologics-license-application-for-fda-approval-of-palifermin/
US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung...US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung...
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) for the treatment of patients with locally advanced (Stage III) unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. The FDA has granted Imfinzi Priority Review status.. The US FDA sBLA submission acceptance is an important milestone for Imfinzi in a disease state where patients need better treatment options and outcomes. Currently, the standard of care for patients with this earlier stage of lung disease is active monitoring following concurrent chemoradiation.. The sBLA submission is based on positive progression-free survival (PFS) data from the Phase III PACIFIC trial. The trial continues to evaluate overall survival (OS), its other primary endpoint. Detailed results of the PACIFIC trial, ...
https://www.astrazeneca.com/investor-relations/Stock-exchange-announcements/us-fda-accepts-supplemental-biologics-license-application-for-imfinzi-in-locally-advanced-unresectable-non-small-cell-lung-cancer-171017.html
Auxilium Pharmaceuticals, Inc. Submits Supplemental Biologics License Application to the FDA forAuxilium Pharmaceuticals, Inc. Submits Supplemental Biologics License Application to the FDA for
MALVERN, Pa., Nov. 7, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. Submits Supplemental Biologics License Application to the FDA for XIAFLEX® for...
https://www.prnewswire.com/news-releases/auxilium-pharmaceuticals-inc-submits-supplemental-biologics-license-application-to-the-fda-for-xiaflex-for-the-treatment-of-peyronies-disease-177623201.html
Roche - FDA accepts Roches supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and...Roche - FDA accepts Roches supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and...
Basel, 17. Januar 2019. Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the companys supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. The FDA is expected to make a decision on approval by 2 September 2019.. We look forward to working with the FDA in order to bring this Tecentriq-based combination to people with non-squamous non-small cell lung cancer as soon as possible, said Sandra Horning, MD, Roches Chief Medical Officer and Head of Global Product Development. Lung cancer is a challenging disease to treat, and this review takes us one step closer towards offering a new treatment option that has shown a clinically meaningful survival ...
https://www.roche.com/de/media/releases/med-cor-2019-01-17.htm
Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2...Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced completing the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for Kadcyla® (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment o...
https://www.pharmiweb.com/press-release/2019-02-05/genentech-submits-supplemental-biologics-license-application-to-fda-for-kadcyla-for-adjuvant-treatme
Vericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the KneeVericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee
CAMBRIDGE, Mass., Jan. 04, 2016-- Vericel Corporation, a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for MACI™, the company s investigational autologous cellular product...
https://www.cnbc.com/2016/01/04/globe-newswire-vericel-submits-biologics-license-application-to-the-fda-for-maci-for-the-treatment-of-cartilage-defects-in-the-knee.html
Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® ...
INCHEON, Republic of Korea & JERUSALEM--(BUSINESS WIRE)--Jul. 31, 2017-- Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: T, Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® (trastuzumab)
http://tevapharm.com/news/celltrion_and_teva_announce_u_s_fda_acceptance_of_biologics_license_application_for_proposed_biosimilar_to_herceptin_trastuzumab_07_17.aspx
Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous (Human) | Business...Emergent BioSolutions Submits Biologics License Application to FDA for Anthrax Immune Globulin Intravenous (Human) | Business...
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (
https://www.businesswire.com/news/home/20140807005237/en/Emergent-BioSolutions-Submits-Biologics-License-Application-FDA
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema...Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema...
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks PR Newswire LEIDEN, The Netherlands, November 27, 2017
https://www.pharmiweb.com/PressReleases/pressrel.asp?row_id=253712
Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T...
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Dr
https://www.enhancedonlinenews.com/news/eon/20170620005552/en
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China |...EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China |...
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China - read this article along with other careers information, tips and advice on BioSpace
https://www.biospace.com/article/releases/eusa-pharma-and-beigene-announce-acceptance-of-a-biologics-license-application-for-qarziba-dinutuximab-beta-in-china/
FDA Encourages Use of Race in Clinical Drug Trials, Health Law & Policy InstituteFDA Encourages Use of Race in Clinical Drug Trials, Health Law & Policy Institute
By Phyllis Griffin Epps The Food and Drug Administration (FDA) is finalizing guidelines that would recommend the use of racial and ethnic categories in clinical drug trials and the submission of data regarding the safety and efficacy of pharmaceutical products subject to FDA approval. The draft guidance, titled Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials (http://www.fda.gov/OHRMS/DOCKETS/98fr/03-2162.pdf ) and issued in January 2003, has as its premise the 1998 final rule of Investigational New Drug Applications and New Drug Applications (the Demographic Rule ). 63 Federal Register 6854 (Feb. 11, 1998) (codified at 21 CFR 312.33(a) (2) and 21 CFR 314.50(d) (5)). A commentary on the Demographic Rule, which requires sponsors of New Drug Applications to include an analysis of data according to demographic subgroups, the draft guidance recommends use of the categories developed by the Office of Management and Budget ( OMB ) to standardize the collection and use of ...
https://www.law.uh.edu/healthlaw/perspectives/Research/031125Muddied.html
Sanjay Sehgal, Ph.D - Regener-Eyes®Sanjay Sehgal, Ph.D - Regener-Eyes®
Sanjay Sehgal, Ph.D. Chief Regulatory Affairs and Quality Assurance Officer Dr. Sehgals core expertise includes regulatory strategy development, authoring and reviewing regulatory submissions, and negotiating approvals for New Drug Applications (NDAs). Sanjay has led and/or supported the regulatory strategy development for multiple Investigational New Drug Applications and NDAs, and has negotiated approvals for eleven (11) […]
https://www.regenereyes.com/sanjay-sehgal-ph-d/
A New Product (VariZIG ) for Postexposure Prophylaxis of Varicella Available Under an Investigational New Drug Application...A New Product (VariZIG ) for Postexposure Prophylaxis of Varicella Available Under an Investigational New Drug Application...
Investigational VariZIG is produced by Cangene Corporation (Winnipeg, Canada) and is distributed by FFF Enterprises (Temecula, California). An expanded access protocol under the IND application enables use of investigational VariZIG for patients who meet the protocols enrollment criteria and who choose to participate. The expanded access protocol has received central institutional review board (IRB) approval. With this central IRB review and approval, FDA does not require an additional approval by the IRB at the treatment site. However, some institutions might require that the institutions IRB be notified before the institution or its physicians participate in a study reviewed by a central IRB. In such cases, notification and any local IRB review may take place before a patient who needs the investigational product is identified. However, if a patient who needs the investigational product is identified before any required local IRB review has taken place, the investigational product may be ...
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a5.htm
Alimera Sciences Announces Resubmission of New Drug Application for ILUVIEN(R) - Business - Press Releases | NBC NewsAlimera Sciences Announces Resubmission of New Drug Application for ILUVIEN(R) - Business - Press Releases | NBC News
ATLANTA, May 13, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the resubmission on May 12, 2011 of its New Drug Application for the investigational drug ILUVIEN® to the U.S. Food and Drug Administration (FDA). The resubmission addresses questions raised in the Complete Response Letter (CRL) received in December 2010.
http://www.nbcnews.com/id/43020874/ns/business-press_releases/
Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections :: Ligand...Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections :: Ligand...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for approval of IV and oral Baxdela™ (delafloxacin) for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Baxdela is an investigational anionic fluoroquinolone with a broad spectrum of antimicrobial activity, including activity against methicillin-resistant Staphylococcus aureus (MRSA). Melintas NDAs are based on the results of two Phase 3 studies (NCT01811732 and NCT01984684), in both of which Baxdela met the primary endpoint of non-inferiority to a combination regimen of vancomycin plus aztreonam in reducing lesion size at the primary infection site at 48-to-72 hours. In addition, Baxdela met the primary endpoint, the investigator ...
https://www.ligand.com/news-events/press-releases/detail/306/ligand-partner-melinta-therapeutics-submits-baxdela-new
Antares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone Nasdaq:ATRSAntares Pharma Announces FDA Acceptance of New Drug Application for Quickshot® Testosterone Nasdaq:ATRS
EWING, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the New Drug Application (NDA) for QuickShot® Testosterone (QST), a drug-device combination product for the delivery of testosterone enanthate using a subcutaneous auto injector, has been accepted for standard review by the U.S Food and Drug Administration (FDA). QST was developed to treat adult men with low testosterone associated with a diagnosed condition known as hypogonadism. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of October 20, 2017, ten months from the official NDA submission. The PDUFA date is the target date for the FDA to complete its review of the NDA.. The FDAs acceptance of the QuickShot testosterone NDA is an important start to the review process and marks another significant milestone for our Company, said Robert F. Apple, President and Chief Executive Officer. We continue to believe QST could be an excellent treatment option for men with ...
http://globenewswire.com/news-release/2017/02/27/927935/0/en/Antares-Pharma-Announces-FDA-Acceptance-of-New-Drug-Application-for-Quickshot-Testosterone.html?f=22&fvtc=5&fvtv=34304652
Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy |...Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy |...
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Ionis (NASDAQ:IONS) today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of nusinersen, an investigational treatment for spinal muscular atrophy (SMA). Biogen has also applied for Priority Review which, if granted, would shorten the review period of nusinersen following the Agencys acceptance of the NDA.
http://media.biogen.com/press-release/neurodegenerative-diseases/biogen-completes-rolling-submission-new-drug-application-fd
Anacor Pharmaceuticals Announces That It Has Submitted a New Drug Application to the FDA for Tavabor - AOL FinanceAnacor Pharmaceuticals Announces That It Has Submitted a New Drug Application to the FDA for Tavabor - AOL Finance
Anacor Pharmaceuticals Announces That It Has Submitted a New Drug Application to the FDA for Tavaborole PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals (NAS: ANAC) announced today
https://www.aol.com/article/finance/2013/07/29/anacor-pharmaceuticals-announces-that-it-has-submi/20679717/
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major...Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major...
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Companys New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.. Priority Review is granted by the FDA to applications for medicines that, if approved, would provide significant improvements in the effectiveness or safety of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. In general, the FDAs Priority Review designation accelerates the review time from 10 months to a goal of six months from the date of acceptance of the filing. The FDA has set a ...
https://www.drugs.com/nda/axs_05_210426.html
U.S. Food and Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational...U.S. Food and Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational...
NEW YORK & SAN DIEGO-- Pfizer Inc. (NYSE: PFE) and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis. The FDA Prescription Drug User Fee Act (PDUFA) date is October 3, 2013. BZA/CE pairs the selective estrogen receptor modulator (SERM) bazedoxifene with conjugated estrogens. BZA/CE has been studied in a Phase III clinical development program (Selective estrogens, Menopause And Response to Therapy [SMART] trials), which included approximately 7,500 postmenopausal women and assessed the safety and efficacy of BZA/CE for the treatment of moderate-to-severe VMS and VVA associated with ...
https://www.ligand.com/news-events/press-releases/detail/49/u-s-food-and-drug-administration-fda-accepts-new-drug
Antares Pharma Announces Submission of New Drug Application for OTREXUP - Drugs.com MedNewsAntares Pharma Announces Submission of New Drug Application for OTREXUP - Drugs.com MedNews
Dec 17, 2012 - Antares Pharma, Inc. (NASDAQ ATRS) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
https://www.drugs.com/clinical_trials/antares-pharma-announces-submission-new-application-otrexup-14952.html
Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid...Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid...
Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders - - Novato (California)
https://news.novatoonline.us/press-releases/ultragenyx-announces-submission-of-new-drug-application-to-fda-for-ux007-triheptanoin-for-treatment-of-long-chain-fatty-acid-oxidation-disorders-292014
Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of...Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of...
PRINCETON, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--April 27, 2006--Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of a product that combines the anti-HIV medications Sustiva(R) (efavirenz), manufactured by Bristol-Myers Squibb, and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead Sciences, in a once-daily single tablet regimen. Truvada itself is a fixed-dose product that contains two of Gileads anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine), in a single once-daily tablet. If approved by the FDA, the new single tablet regimen would be the first and only product that contains a complete Highly Active Antiretroviral Therapy (HAART) regimen in a single once-daily tablet, intended for the treatment of HIV-1 infection in adults as a complete regimen or in ...
http://www.gilead.com/news/press-releases/2006/4/bristolmyers-squibb-and-gilead-sciences-submit-new-drug-application-to-us-fda-for-a-oncedaily-single-tablet-regimen-of-sustivar-efavirenz-and-truvadar-emtricitabine-and-tenofovir-disoproxil-fumarate-for-hiv-treatment?mode=print
Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting...Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting...
This final rule is expected to improve the quality of safety reports submitted to FDA, thereby enhancing the safety of patients in clinical trials. The final rule lays out clear definitions and standards so that critical safety information about investigational new drugs will be accurately and rapidly reported to the agency, minimizing uninformative reports and enhancing reporting of meaningful, interpretable information ...
https://www.fda.gov/drugs/investigational-new-drug-ind-application/final-rule-investigational-new-drug-safety-reporting-requirements-human-drug-and-biological-products
Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Submits New Drug Application for ARX-04 for the Treatment of Moderate...Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Submits New Drug Application for ARX-04 for the Treatment of Moderate...
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced that it has submitted a New Drug Application (NDA) under section 505(b)(2) with the U.S. Food and Drug
https://www.smarteranalyst.com/2016/12/13/company-update-nasdaqacrx-acelrx-pharmaceuticals-inc-submits-new-drug-application-arx-04-treatment-moderate-severe-acute-pain/
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir,...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
https://www.enhancedonlinenews.com/news/eon/20170612005566/en
FDA gives new drug application approval to IsisFDA gives new drug application approval to Isis
Drug developer Isis Pharmaceuticals Inc. and partner Genzyme announced Tuesday that the U.S. Food and Drug Administration has approved their new drug application for Kynamro, clearing the way for Isis ...
https://www.yahoo.com/news/fda-gives-drug-application-approval-010157127.html?.tsrc=samsungwn&ref=gs
FDA Continues Review Of Crofelemer New Drug Application Beyond PDUFA Goal Date Of September 5, 2012 - TheStreetFDA Continues Review Of Crofelemer New Drug Application Beyond PDUFA Goal Date Of September 5, 2012 - TheStreet
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration has advised the Company that its New Drug Application (NDA) for crofelemer 125 mg tablets, for the proposed indication of......SLXP
https://www.thestreet.com/story/11685258/1/fda-continues-review-of-crofelemer-new-drug-application-beyond-pdufa-goal-date-of-september-5-2012.html
New Drug Application For Naloxegol Accepted By United States Food And Drug AdministrationNew Drug Application For Naloxegol Accepted By United States Food And Drug Administration
SAN FRANCISCO, Nov. 19, 2013 /PRNewswire/ -- New Drug Application For Naloxegol Accepted By United States Food And Drug Administration.
https://www.prnewswire.com/news-releases/new-drug-application-for-naloxegol-accepted-by-united-states-food-and-drug-administration-232477581.html
FDA Accepts New Drug Application for Sublingual Apomorphine to Treat Motor Fluctuations - Practical NeurologyFDA Accepts New Drug Application for Sublingual Apomorphine to Treat Motor Fluctuations - Practical Neurology
The Food and Drug Administration (FDA) has accepted a new drug application (NDA) for apomorphine sublingual film (APL-130277; Sunovion, Marlborough, M
https://practicalneurology.com/news/fda-accepts-new-drug-application-for-sublingual-apomorphine-to-treat-motor-fluctuations?c4src=topic:movement-disorders:feed
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with...FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with...
KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with bevacizumab has been accepted and granted priority review by the U.S.
https://www.mrknewsroom.com/news-release/oncology/fda-accepts-regulatory-submission-supplemental-new-drug-application-lynparza-o
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA)...Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA)...
SHANGHAI, CHINA, Apr 23, 2021 - (ACN Newswire via SEAPRWire.com) - Hua Medicine (the Company, Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). Dorzagliatin is the first glucokinase activator (GKA) to submit a NDA for the treatment of diabetes, and has the potential to become the first first-in-class drug to be launched in China. Relying on Hua Medicines original scientific concept of repair the sensor, restore homeostasis, and treat the underlying cause of diabetes, the Company has always focused on addressing unmet medical needs since its establishment. The Company is committed to developing breakthrough products with innovative concepts, and advancing and establishing clinical practice and treatment standards globally. Dorzagliatin is the worlds first new GKA diabetes drug for which a NDA has been submitted, with a new mechanism ...
https://seatribune.com/acn-newswire/hua-medicine-announces-acceptance-of-a-new-drug-application-for-dorzagliatin-in-china-first-glucokinase-activator-gka-globally/
Merck Announces FDA Acceptance Of New Drug Application For Suvorexant, An Investigational Insomnia Medicine - TheStreetMerck Announces FDA Acceptance Of New Drug Application For Suvorexant, An Investigational Insomnia Medicine - TheStreet
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company's investigational insomnia medicine, has been accepted for standard......MRK
https://www.thestreet.com/story/11760867/1/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine.html
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre...Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre...
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Dr
https://www.businesswire.com/news/home/20190405005180/en/
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product - Full Text View - ClinicalTrials.govLong-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product - Full Text View - ClinicalTrials.gov
Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access program, or equivalent setting. No investigational product or treatment will be administered in this study. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products ...
https://www.clinicaltrials.gov/ct2/show/NCT02840110
United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis |...United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis |...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 9, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF). United Therapeutics intends to initiate a phase 3 study, called TETON, to evaluate the use of Tyvaso® (treprostinil) Inhalation Solution in patients with IPF. FDA recently cleared United Therapeutics investigational new drug application (IND) for the TETON study, and the company expects to commence enrollment in 2021. Orphan drug designation is the first step in receiving orphan drug exclusivity following approval, which confers seven years of market exclusivity for the relevant indication. This exclusivity would also benefit Treprostinil Technosphere®, United Therapeutics next-generation dry powder inhalation form of treprostinil, upon FDA approval of that product for ...
https://ir.unither.com/news/press-releases/press-release-details/2020/United-Therapeutics-Receives-FDA-Orphan-Drug-Designation-For-Treprostinil-For-The-Treatment-Of-Idiopathic-Pulmonary-Fibrosis/default.aspx
Cerium Oxide Nanoparticles in the Treatment of Parkinson s Disease Toxicity and Biodistribution Studies | Parkinsons DiseaseCerium Oxide Nanoparticles in the Treatment of Parkinson s Disease Toxicity and Biodistribution Studies | Parkinsons Disease
Based on these very promising results, our supplemental investigation proposes to conduct studies that will enable the filing of an Investigational New Drug application, to further move CeONP down the drug development pipeline. Prior to a drug being tested for human use, safety, toxicity, and pharmacokinetic studies need to be performed to assure the drug will be relatively safe. We will conduct these studies in our supplemental investigation. Immediate safety and toxicity will be assessed at two doses. Additionally, we will determine how CeONP are distributed in the body and determine what organs they accumulate in. We will examine tissues for histopathology and adverse effects. Further, since nanoparticles may persist in the system after initial delivery, we will also examine histopathology and biodistribution at six months after administration ...
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1066
Efficacy of crosseal fibrin sealant (Human) in rhytidectomy<...
TY - JOUR. T1 - Efficacy of crosseal fibrin sealant (Human) in rhytidectomy. AU - Lee, Samson. AU - Pham, Annette M.. AU - Pryor, Shepherd G.. AU - Tollefson, Travis Tate. AU - Sykes, Jonathan M. PY - 2009/1. Y1 - 2009/1. N2 - Objective: To examine the potential efficacy of Crosseal (the human protein, bovine component-free fibrin sealant) (OMRIX Biopharmaceuticals, Ltd, Brussels, Belgium) to reduce ecchymoses and hematoma formation in patients undergoing rhytidectomy. Methods: Before initiation of the study, approval was obtained from the US Food and Drug Administration for an Investigational New Drug Application and off-label use of Crosseal and from the Institutional Review Board of the University of California, Davis. Patients undergoing rhytidectomy with or without concomitant procedures were voluntarily enrolled without compensation in the study (N=9). Patients were randomized according to which side of the rhytidectomy the tissue sealant was placed. In all patients in the study, 1 side of ...
https://ucdavis.pure.elsevier.com/en/publications/efficacy-of-crosseal-fibrin-sealant-human-in-rhytidectomy
UAB Spinoff Targets Cancer with Drug-Resistant Immunotherapy, a Novel Approach to Fighting Tumors | UAB Comprehensive Cancer...
The University of Alabama at Birmingham and two partner institutions this month received a European patent for their novel approach to fighting cancer, an approach that is led by the UAB spinoff biopharmaceutical company Incysus Ltd.. Incysus is focused on delivering innovative cellular therapy to treat solid tumor cancers. The European patent is owned by the academic collaborators of Incysus - UAB, Emory University and Childrens Healthcare of Atlanta - and it is licensed exclusively to Incysus for all therapeutic purposes. U.S. Patent applications are pending.. The novel cellular therapy is called drug-resistant immunotherapy, or DRI. It is in its preclinical phase, and Incysus is moving toward an investigational new drug application filing with the U.S. Food and Drug Administration to begin tests of safety and efficacy in patients with the brain tumor glioblastoma.. DRI combines two ways to fight cancer - immunotherapy and chemotherapy. While chemotherapy can shrink tumors, immunotherapy uses ...
http://www3.ccc.uab.edu/newsroom/uab-spinoff-targets-cancer-with-drug-resistant-immunotherapy-a-novel-approach-to-fighting-tumors/
6:56 am6:56 am
With no cure and persistence of seizures with current antiepileptic medications, the orphan drug designation recognizes the significant, unmet need that exists among children with this severe form of epilepsy and the teams who provide their care, said Michael L. Babich, President and Chief Executive Officer. We have the unique opportunity to test a controlled pharmaceutical CBD product for Lennox-Gastaut Syndrome, and our company is committed to advancing cannabinoid therapies that have the potential to provide significant medical benefits to patients across multiple indications. We expect to file an Investigational New Drug Application (IND) for CBD in the second half of 2014.. Insys, which has more than seven years of research and development experience in the pharmaceutical cannabinoid space, manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD, both of which are cannabinoids, at its FDA-inspected and Drug Enforcement Administration(DEA) approved facility, located in Round ...
https://www.azbio.org/insys-therapeutics-receives-fda-orphan-drug-designation-for-its-pharmaceutical-cannabidiol-as-a-potential-treatment-for-rare-form-of-epilepsy-lennox-gastaut-syndrome
Rare Cancer News & Clinical Trials » PubMed - Neuroendocrine TumorRare Cancer News & Clinical Trials » PubMed - Neuroendocrine Tumor
Purpose To assess the clinical safety, pharmacokinetics, and tumor imaging characteristics of fluorine 18-(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent. Materials and Methods This study was approved by the institutional review board and conducted under a U.S. Food and Drug Administration-approved Investigational New Drug application in accordance with the Helsinki Declaration and the Health Insurance Portability and Accountability Act. All patients provided written informed consent. Between January 2013 and October 2016, 25 adult patients with cancer received an intravenous bolus of FGln tracer (mean, 244 MBq ± 118, ,100 μg) followed by positron emission tomography (PET) and blood radioassays. Patient data were summarized with descriptive statistics. FGln biodistribution and plasma amino acid levels in nonfasting patients (n = 13) were compared with those from patients who fasted at least 8 hours before injection (n = 12) by using nonparametric one-way analysis ...
http://news.rare-cancer.org/PubMed_-_Neuroendocrine_Tumor/
Amgen Submits Supplemental Biologics License Application For BLINCYTO BlinatumomabAmgen Submits Supplemental Biologics License Application For BLINCYTO Blinatumomab
BLINCYTO® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation.. Warnings and Precautions. Cytokine Release Syndrome (CRS): Life-threatening or fatal CRS occurred in patients receiving BLINCYTO®. Infusion reactions have occurred and may be clinically indistinguishable from manifestations of CRS. Closely monitor patients for signs and symptoms of serious events such as pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Interrupt or discontinue BLINCYTO® as outlined in the Prescribing Information (PI). Neurological Toxicities: Approximately 50% of patients receiving BLINCYTO® in clinical trials experienced neurological toxicities. Severe, ...
https://www.amgen.com/media/news-releases/2016/03/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab/
Green Pasture Fermented Cod Liver Oil 120 caps - Spirit of Health StoreGreen Pasture Fermented Cod Liver Oil 120 caps - Spirit of Health Store
Is Fermented Cod Liver Oil raw? Yes. Unlike all unfermented cod liver oil on the market, Fermented Cod Liver Oil is not subjected to temperature above 110 degrees.. How do I store Fermented Cod Liver Oil? It is OK to store in your pantry before opening, but you should refrigerate after opening.. How many capsules are in a jar of Fermented Cod Liver Oil capsules? 120 capsules. Expiration Dates vs. Manufacture Dates:. All manufactures of dietary supplements must have in place the FDAs updated compliancy regulations called current good manufacturing practices (cGMPs). What does this mean to you, the consumer? Within these lengthy new regulations come several confusing surprises. One of these new surprises is the use of Manufacture date verses Expiration date. You will see either an Expiration Date or Manufacture Date on your supplements. Since the FDA published their Final Rule on 21CFR Part 111 in 2007 for current good manufacturing practices (cGMPs) they have given manufactures the option of ...
https://store.spiritofhealthkc.com/green-pasture-fermented-cod-liver-oil-120-caps/?revpage=2
Clinical Trial Materials Manufacturing ServicesClinical Trial Materials Manufacturing Services
GMP clinical trial material manufacturing services to meet your supply needs for investigational medicinal product (IMP) or investigational new drugs (IND) for clinical trials around the world Clinical trial materials manufacturing, to meet the supply needs of Phase I and II pharmaceutical clinical trials, requires a flexible and consistent contract services partner. Whilst sourcing high-quality supplies within trial timelines, you will need clinical trial supply manufacturing that is both fully GMP compliant and responsive.. Our clinical trial supplies manufacturing services are delivered from our state-of-the-art Good Manufacturing Practice (GMP) compliant facilities supporting investigational medicinal product (IMP) or investigational new drugs (IND) for clinical trials around the world ...
https://www.intertek.com/pharmaceutical/clinical-trial-materials-manufacturing/
Alimera Announces PDUFA Goal Date for Iluvien - The American Society of Retina SpecialistsAlimera Announces PDUFA Goal Date for Iluvien - The American Society of Retina Specialists
Alimera Sciences, Inc. (Atlanta, GA) has announced that its recent resubmission of the New Drug Application (NDA) for Iluvien (sustained-release fluocinolone acetonide implant) has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDAs October 2013 letter. The FDA has set September 26, 2014 as the Prescription Drug User Fee Act (PDUFA) goal date.. In the resubmission, Alimera responded to questions raised in the FDAs October 2013 letter and provided data from Iluvien patients and from physician experience with the applicator in the United Kingdom and Germany, where Iluvien is currently commercially available. Iluvien has also received marketing authorization in Austria, the United Kingdom, Portugal, France, Germany, and Spain.. Also read: Alimera Resubmits New Drug Application for Iluvien. Updated April 15, 2014. ...
http://www.asrs.org/education/clinical-updates/244/
pSivida Granted Waiver by the FDA for New Drug Application Filing Fee | EyePoint PharmaceuticalspSivida Granted Waiver by the FDA for New Drug Application Filing Fee | EyePoint Pharmaceuticals
President and CEO.. About pSivida Corp.. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSividas lead product candidate, Durasert™ micro-insert for posterior segment uveitis, is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint of prevention of recurrence of uveitis at six months of follow-up with statistical significance, and the Company plans to file an NDA in early January 2018. pSividas pre-clinical development program is focused on using its core platform ...
http://investors.eyepointpharma.com/news-releases/news-release-details/psivida-granted-waiver-fda-new-drug-application-filing-fee
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing...Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing...
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that we may not file a marketing authorization for R/F/TAF in the European Union in the currently anticipated timelines. In addition, there is the possibility that the FDA and other regulatory authorities may not approve F/TAF, E/C/F/TAF, R/F/TAF, D/C/F/TAF or other F/TAF-based regimens in the currently anticipated timelines or at all, and marketing approvals, if granted, may have significant limitations on their use. As a result, F/TAF, E/C/F/TAF, R/F/TAF, D/C/F/TAF and other F/TAF-based regimens may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are ...
http://www.natap.org/2015/HIV/070215_01.htm
FDA grants priority review for Cysview® supplemental New Drug Application (sNDA) - PhotocureFDA grants priority review for Cysview® supplemental New Drug Application (sNDA) - Photocure
The company is looking to expand the label of Cysview to include its use in the outpatient setting to detect the recurrence of bladder cancer using a flexible cystoscope, the detection of carcinoma in situ (CIS) and the repeat administration of Cysview. The filing is a combination drug-device application, with the KARL STORZ D-LIGHT C PDD Flexible Videoscope System.. We are delighted to see the FDA expedite the review for this sNDA as it will offer patients improved surveillance of their Non-Muscle Invasive Bladder Cancer (NMIBC), commented Andrea Maddox-Smith CEO, Bladder Cancer Advocacy Network (BCAN). BCAN is the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease.. We look forward to hearing a decision from the FDA early next year on the US Cysview® label expansion to include patients undergoing surveillance cystoscopy using a flexible scope. The sNDA also includes detection of CIS and to allow for repeated use in ...
https://www.photocure.com/Pressmedia/News/Cysview-sNDA/
Norethindrone / norethindrone FDA New drug application 091325 international drug patent coverage, generic alternatives and...Norethindrone / norethindrone FDA New drug application 091325 international drug patent coverage, generic alternatives and...
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...
https://www.drugpatentwatch.com/p/NDA/091325
Lorazepam / lorazepam FDA New drug application 072555 international drug patent coverage, generic alternatives and suppliersLorazepam / lorazepam FDA New drug application 072555 international drug patent coverage, generic alternatives and suppliers
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...
https://www.drugpatentwatch.com/p/NDA/072555
N6-CyclopentyladenosineN6-Cyclopentyladenosine
Expert Opinion on Investigational Drugs. 17 (12): 1901-1910. doi:10.1517/13543780802497284. PMID 19012505. S2CID 74182151. ... Elzein E, Zablocki J (December 2008). "A1 adenosine receptor agonists and their potential therapeutic applications". ... N6-Cyclopentyladenosine (CPA) is a drug which acts as a selective adenosine A1 receptor agonist. It has mainly cardiovascular ...
https://en.wikipedia.org/wiki/N6-Cyclopentyladenosine
Medical cannabis researchMedical cannabis research
... potential therapeutic applications". Expert Opinion on Investigational Drugs (Review). 12 (1): 39-49. doi:10.1517/13543784.12. ... and a license must be obtained from the Drug Enforcement Administration specific to Schedule I drugs. The FDA has 30 days to ... The PHS review was not performed for any other Schedule I drugs, and had no deadline imposed. In addition to the FDA and DEA ( ... This monopoly maintained by the DEA did not exist for other Schedule I drugs, and there was no deadline established for the ...
https://en.wikipedia.org/wiki/Medical_cannabis_research
Human embryonic stem cells clinical trialsHuman embryonic stem cells clinical trials
Researchers must complete an Investigational New Drug (IND) application in order to earn the FDA's approval. IND applications ... U.S. Food and Drug Administration. (2011). "Investigational New Drug (IND) Application." Retrieved April 12, 2012, from https ... Testing for new drugs must successfully go through three phases of research before a drug can be marketed to the public. In ... drug manufacturing information explaining how and where the drug will be produced, and a detailed research protocol stating who ...
https://en.wikipedia.org/wiki/Human_embryonic_stem_cells_clinical_trials
Keystone NanoKeystone Nano
In January 2017, the FDA approved the investigational new drug application, NanoLiposome, to assess the product as a form of ... "FDA Approves Investigational New Drug Application for Ceramide NanoLiposome". Pharmacy Times. Retrieved 14 January 2017. " ... "Investigational cancer compound receives FDA approval to begin human trials". Penn State News. Official website (Orphaned ...
https://en.wikipedia.org/wiki/Keystone_Nano
ViralyticsViralytics
"Allowance of FDA Investigational New Drug (IND) Application for Cavatak Phase II Melanoma Trial" (PDF). asx.com.au. 27 June ... "Investigational New Drug Application Lodged With the FDA" (PDF). asx.com.au. 3 November 2010. Retrieved 4 December 2015. " ... This trial took place under an Investigational New Drug application. The trial completed in 2015 with favourable results and ... The drug was granted Orphan Drug status in advanced melanoma in December 2005. Around 1999 a team led by the virologist ...
https://en.wikipedia.org/wiki/Viralytics
Chemical graph generatorChemical graph generator
... flexible molecular descriptors with applications from physical chemistry to ADME". IDrugs: the Investigational Drugs Journal. 9 ... 1. Application to the Structure Elucidation of Large Molecules". Journal of Chemical Information and Computer Sciences. 34 (5 ... Raymond E. Carhart; Dennis H. Smith; Neil A. B. Gray; James G. Nourse; Carl Djerassi (April 1981). "Applications of artificial ... Chemical graph generators are used in areas such as virtual library generation in drug design, in molecular design with ...
https://en.wikipedia.org/wiki/Chemical_graph_generator
RabeprazoleRabeprazole
... the pre-investigational new drug application was submitted on October 28, 1998. The final investigational new drug application ... "Application Number 20-973/S-009" (PDF). Center for Drug Evaluation and Research. Retrieved 13 October 2017. Lombardo, Carla; ... Center for Drug Evaluation and Research. Retrieved 3 December 2017. "Drugs@FDA". accessdata.fda.gov. US FDA. Retrieved 9 ... Clinically serious drug-drug interactions may involve the acid-suppression effects of rabeprazole. For example, rabeprazole ...
https://en.wikipedia.org/wiki/Rabeprazole
List of Guidances for Statistics in Regulatory AffairsList of Guidances for Statistics in Regulatory Affairs
FDA: Good Review Practice: Clinical Review of Investigational New Drug Applications. This good review practice (GRP) document ... The randomization is discussed in: FDA: Good Review Practice: Clinical Review of Investigational New Drug Applications, chapter ... Clinical Review of Investigational New Drug Applications CHMP/EWP/5872/03 Data monitoring committees FDA - Establishment and ... from the pre-IND phase to the time of the pre-new drug application/biologics license application meeting. CHMP/EWP/5872/03: ...
https://en.wikipedia.org/wiki/List_of_Guidances_for_Statistics_in_Regulatory_Affairs
Investigational New DrugInvestigational New Drug
... (IND) Application Process Center for Drug Evaluation and Research, Food and Drug Administration. ICH ... law to investigational use." Approximately two-thirds of both INDs and new drug applications (NDAs) are small-molecule drugs. ... Abigail Alliance for Better Access to Developmental Drugs Animal drug Biologics license application Drug discovery FDA Fast ... The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical ...
https://en.wikipedia.org/wiki/Investigational_New_Drug
GanaplacideGanaplacide
Expert Opinion on Investigational Drugs. 24 (3): 363-82. doi:10.1517/13543784.2015.1000483. PMID 25563531. S2CID 22547760. ... There are previous US patent applications but only this one has been granted. Held J, Jeyaraj S, Kreidenweiss A (March 2015). " ... This drug was identified by a high throughput screen of over 2 million compounds. This drug is being developed with support ... Articles with short description, Short description matches Wikidata, Drugs not assigned an ATC code, Drugs with non-standard ...
https://en.wikipedia.org/wiki/Ganaplacide
TrefentanilTrefentanil
... application to the investigational opioid trefentanil". Clinical Pharmacology and Therapeutics. 56 (3): 261-71. doi:10.1038/ ... Multiple chemicals in Infobox drug, Chemicals using indexlabels, Chemical articles with multiple CAS registry numbers, Drugs ... Articles with short description, Short description matches Wikidata, Drugs not assigned an ATC code, Chemical pages without ... Lemmens HJ, Dyck JB, Shafer SL, Stanski DR (September 1994). "Pharmacokinetic-pharmacodynamic modeling in drug development: ...
https://en.wikipedia.org/wiki/Trefentanil
Immunoglobulin therapyImmunoglobulin therapy
"FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients". www.businesswire.com. 20 May ... Drugs with non-standard pregnancy category, Drugs with non-standard legal status, Chemicals that do not have a ChemSpider ID ... "Experimental Alzheimer's drug Gammagard may stall memory decline, small study suggests". CBS News. 17 July 2012. Archived from ... "Immune globulin". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Pages containing links to ...
https://en.wikipedia.org/wiki/Immunoglobulin_therapy
Fish oil (medical use)Fish oil (medical use)
Research, Center for Drug Evaluation and. "Investigational New Drug (IND) Application - How to request Omegaven for Expanded ... Drugs not assigned an ATC code, Infobox drug articles with non-default infobox title, Infobox drug articles without a structure ... "Drug Approval Package: Omegaven (fish oil triglycerides)". U.S. Food and Drug Administration (FDA). 24 August 2018. Retrieved ... "Omegaven". Drug Information Portal. U.S. National Library of Medicine. Cooke, Robert (2006-07-03). "How fish oil may have saved ...
https://en.wikipedia.org/wiki/Fish_oil_(medical_use)
Clinical researchClinical research
are submitted in support of an Investigational New Drug (IND) application to the FDA for review prior to conducting studies ... FDA Page last updated 27 October 2014 Investigational New Drug (IND) Application Mohamadi, Amin; Asghari, Fariba; Rashidian, ... "The Drug Development Process; Step 3: Clinical Research". US Food and Drug Administration. 4 January 2018. Retrieved 28 June ... Only 25-30% of drugs advance to the end of Phase III. Before pharmaceutical companies start clinical trials on a drug, they ...
https://en.wikipedia.org/wiki/Clinical_research
Experimental drugExperimental drug
Off-label treatment List of investigational drugs Mahant, Vijay (2020-06-23). ""Right-to-Try" experimental drugs: an overview ... IND status requires the drug's sponsor to submit an IND application that includes data from laboratory and animal testing for ... "How Drugs are Developed and Approved". U.S. Food and Drug Administration. Retrieved July 27, 2018. "How Drugs are Reviewed in ... An experimental drug is a medicinal product (a drug or vaccine) that has not yet received approval from governmental regulatory ...
https://en.wikipedia.org/wiki/Experimental_drug
ClinafloxacinClinafloxacin
The investigational new drug application was withdrawn by the manufacturer in 1999, citing safety concerns. Clinafloxacin is ... drug-induced light sensitivity, and multiple drug-drug interactions. Clinical trials have been done to assess its efficacy in ... Multiple chemicals in Infobox drug, Chemicals using indexlabels, Chemical articles with multiple CAS registry numbers, Drugs ... About half of an administered clinafloxacin dose is found unchanged in the urine, meaning that the drug is cleared from the ...
https://en.wikipedia.org/wiki/Clinafloxacin
SolithromycinSolithromycin
In 2008, investigational new drug applications for solithromycin capsules and an intravenous formulation were submitted. From ... July 2016: Cempra announced FDA acceptance of IV and oral formulations of Solithera (solithromycin) new drug applications for ... "Cempra Announces FDA Acceptance of Solithera™ New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia ... Additionally, there are significant drug-drug interactions affecting solithromycin concentrations as well the concentrations of ...
https://en.wikipedia.org/wiki/Solithromycin
SUGENSUGEN
... went public in October 1994 (NASDAQ: SUGN). In 1997, it filed its first Investigational New Drug (IND) application, for a ... "SU11248: Genesis of a New Cancer Drug". The Scientist. 19: 17-24. Archived from the original on 19 April 2005. "Making a Rush ... SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and ... Pfizer continued the phase 3 trials and development of SU11248, now known as Sutent (sunitinib), leading to Food and Drug ...
https://en.wikipedia.org/wiki/SUGEN
BrigatinibBrigatinib
filed an investigational new drug (IND) application to the US FDA on August 29, 2016. In 2016, brigatinib was granted orphan ... Drugs with non-standard legal status, Articles without EBI source, Chemical pages without DrugBank identifier, Drug has EMA ... "Brigatinib". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (All articles with dead external ... On 28 April 2017, it was granted an accelerated approval from the U.S. Food and Drug Administration (FDA) for metastatic non- ...
https://en.wikipedia.org/wiki/Brigatinib
Ebola virus cases in the United StatesEbola virus cases in the United States
"Chimerix Announces Emergency Investigational New Drug Applications for Brincidofovir Authorized by FDA for Patients With Ebola ... They both recovered, but there was no confirmation or proof that the drug was a factor. A Spanish priest with Ebola had taken ... "Pre-application Webinar Agenda "Opportunities for Collaborative Research at the NIH Clinical Center" X02 (PAR-13-357) and U01 ( ... There is as yet no medication or vaccine for Ebola approved by the U.S. Food and Drug Administration (FDA).[citation needed] ...
https://en.wikipedia.org/wiki/Ebola_virus_cases_in_the_United_States
Expanded accessExpanded access
... and The person is unable to obtain the investigational drug or device under another IND application (for drugs), IDE ... use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or ... The Alliance seeks broader availability of investigational drugs on behalf of people with terminal illnesses. It is best known ... Drugs can be made available to individuals, small groups, or large groups. In the US, actual provision of the drug depends on ...
https://en.wikipedia.org/wiki/Expanded_access
Rosetta@home[email protected]
In December 2020, Neoleukin announced it would be submitting an Investigational New Drug application with the Food and Drug ... "Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy ... This type of protein design could have future applications in drug discovery, green chemistry, and bioremediation. In addition ... A similar application was submitted in Australia and Neoleukin hopes to enrol up 120 participants on the Phase 1 clinical trial ...
https://en.wikipedia.org/wiki/[email protected]
John J. ZhangJohn J. Zhang
... and requires an Investigational New Drug application. In contrast, the UK became the first country to legalize it, in 2015. ...
https://en.wikipedia.org/wiki/John_J._Zhang
DomperidoneDomperidone
... for use in people with treatment-refractory gastrointestinal symptoms under an FDA Investigational New Drug application. ... gastrointestinal motility problems under an expanded access individual-patient investigational new drug application. An ... 184-. ISBN 978-1-4377-0310-8. Youssef AS, Parkman HP, Nagar S (November 2015). "Drug-drug interactions in pharmacologic ... The drug is a substrate for the P-glycoprotein (ABCB1) transporter, and animal studies suggest that this is the reason for the ...
https://en.wikipedia.org/wiki/Domperidone
Declaration of HelsinkiDeclaration of Helsinki
Foreign clinical studies not conducted under an investigational new drug application. Final Rule April 28 2008, effective ... criticised by Levine was removed to emphasize the more general application of ethical principles, but the application of the ... Health, Center for Drug Evaluation and Research,Center for Biologics Evaluation and Research,Center for Devices and ... The Nation May 19, 2008 "Trials on trial: The Food and Drug Administration should rethink its rejection of the Declaration of ...
https://en.wikipedia.org/wiki/Declaration_of_Helsinki
4-Chlorokynurenine4-Chlorokynurenine
VistaGen filed an Investigational New Drug application with the FDA for use of AV-101 in neuropathic pain in 2013. In 2013, ... List of investigational antidepressants Park, Lawrence T.; Kadriu, Bashkim; Gould, Todd D.; Zanos, Panos; Greenstein, Deanna; ... Drug Discovery. 12 (1): 64-82. doi:10.1038/nrd3793. PMID 23237916. S2CID 31914015. "School of Medicine Professor Wins ... Enters Late-Stage Preclinical Development Program for Lead Epilepsy Drug Candidate -". PR Newswire. November 19, 2003. " ...
https://en.wikipedia.org/wiki/4-Chlorokynurenine
AmatuximabAmatuximab
Quickly following they opened an Investigational New Drug Application with the FDA in 2006 and initiated Phase I clinical ... Drugs that are a monoclonal antibody, Monoclonal antibodies, Experimental cancer drugs, Orphan drugs). ... The primary focus of the company is development of biological drug products for the treatment of inflammatory disease, cancer, ... The FDA granted amatuximab orphan drug status for use in malignant pleural mesothelioma in November 2012, and the European ...
https://en.wikipedia.org/wiki/Amatuximab
TranylcypromineTranylcypromine
Expert Opinion on Investigational Drugs. 25 (7): 771-80. doi:10.1080/13543784.2016.1175432. PMID 27077938. S2CID 20858344. Al- ... 2016). "Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment". Current Topics ... The use of indirect sympathomimetic drugs or drugs affecting serotonin reuptake, such as meperidine or dextromethorphan poses a ... Smith MS, Muir H, Hall R (February 1996). "Perioperative management of drug therapy, clinical considerations". Drugs. 51 (2): ...
https://en.wikipedia.org/wiki/Tranylcypromine
SciodermScioderm
"Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA ... Drug discovery companies, Pharmaceutical companies of the United States, Technology companies established in 2012, Orphan drug ... Zorblisa is the first drug to ever enter Phase 3 development for the treatment of EB. Stem cell research for Epidermolysis ... Hein, Alexandria (28 July 2015). "Family of NYC girl with skin-blistering condition sees hope in new drug". FoxNews.com. Lupkin ...
https://en.wikipedia.org/wiki/Scioderm
Discovery and development of proton pump inhibitorsDiscovery and development of proton pump inhibitors
In 1980, an Investigational New Drug (IND) application was filed and omeprazole was taken into Phase III human trials in 1982. ... Silverman, Richard B. (2004). "Receptors". The organic chemistry of drug design and drug action (2nd ed.). Academic Press. p. ... PPIs also can bind to other types of proton pumps such as those that occur in cancer cells and are finding applications in the ... These drugs have emerged as the treatment of choice for acid-related diseases, including gastroesophageal reflux disease (GERD ...
https://en.wikipedia.org/wiki/Discovery_and_development_of_proton_pump_inhibitors
CureVac COVID-19 vaccineCureVac COVID-19 vaccine
Drugs not assigned an ATC code, Drugs with non-standard legal status, Infobox drug articles with non-default infobox title, ... "Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 ... "CureVac has withdrawn its Covid vaccine application to European regulators". The New York Times. Retrieved 13 October 2021. " ... Scholia has a profile for zorecimeran (Q97154239). "Zorecimeran". Drug Information Portal. U.S. National Library of Medicine. ...
https://en.wikipedia.org/wiki/CureVac_COVID-19_vaccine
List of Puerto Rican scientists and inventorsList of Puerto Rican scientists and inventors
As of January 1, 2019, he has been awarded over 85 U.S. patents, and is an inventor on over 130 U.S. patent applications. His ... Genetic Roadmap Targets Drug Therapies Archived September 1, 2010, at the Wayback Machine from Hartford Business Review ... implementation and oversight of research protocols in which the use of animals is required for investigational purposes. ... He began working in the Mississippi River plume and in the application of remote sensors to study coastal environments. He co- ...
https://en.wikipedia.org/wiki/List_of_Puerto_Rican_scientists_and_inventors
CX717CX717
In 2005 the U.S. Food and Drug Administration (FDA) accepted Cortex Pharmaceuticals' Investigational New Drug (IND) application ... These drugs were reasonably effective at reducing the symptoms of Alzheimer's and it was hoped that they could also slow the ... Other AMPAkine drugs from Cortex Pharmaceuticals such as CX-546 and CX-614 have already been researched for use in treating ... One data set went to the FDA's Division of Neurology Drug Products for the treatment of Alzheimer's disease, while the other ...
https://en.wikipedia.org/wiki/CX717
List of medical journalsList of medical journals
Toxicology Expert Opinion on Drug Safety Expert Opinion on Emerging Drugs Expert Opinion on Investigational Drugs Expert ... Advances and Applications Clinical Pharmacology & Therapeutics Expert Opinion on Drug Delivery Expert Opinion on Drug Discovery ... Seminars in Cardiothoracic and Vascular Anesthesia The Cleft Palate-Craniofacial Journal List of dental journals Advanced Drug ... Opinion on Pharmacotherapy Indian Journal of Pharmacology The Medical Letter on Drugs and Therapeutics Scientia Pharmaceutica ...
https://en.wikipedia.org/wiki/List_of_medical_journals
GenervonGenervon
... it is in the process of developing three drugs for which it has submitted Investigational New Drug applications which are in ... GM604 is the temporary name of a drug under development by Genervon that is supposed to slow the progression of ALS. The drug ... These drugs seek to treat acute ischemic stroke patients under (IND #77789), Parkinson's disease (IND #10944) and ALS (GM604, ... Silverman, Ed (20 April 2015). "A Dispute Flares Over Data for a Nascent ALS Drug and an FDA Review". The Wall Street Journal. ...
https://en.wikipedia.org/wiki/Genervon
LiposuctionLiposuction
Everything about the surgical suction application via cannula is different from standard suction lipectomy. The goal of FLLA is ... Toxicity from anesthesia due to the use of lidocaine, a skin-numbing drug, can cause lightheadedness, restlessness, drowsiness ... and not investigational, experimental, or unproven, the claim is medically necessary and should be reimbursed. While most ... Journal of Drugs in Dermatology. 10 (12): 1363-9. PMID 22134559. Draelos, Zoe (2011). Cosmetic Dermatology: Products and ...
https://en.wikipedia.org/wiki/Liposuction
Waldenström macroglobulinemiaWaldenström macroglobulinemia
Current Opinion in Investigational Drugs. 9 (6): 631-637. PMID 18516762. Chng, W.; Schop, R.; Price-Troska, T.; Ghobrial, I.; ... therapeutic applications and considerations". Seminars in Oncology. 30 (2): 248-252. doi:10.1053/sonc.2003.50047. PMID 12720146 ... Based on this study, the Food and Drug Administration approved ibrutinib for use in Waldenström macroglobulinemia in 2015. ... "FDA approves zanubrutinib for Waldenström's macroglobulinemia". U.S. Food and Drug Administration (FDA). 1 September 2021. ...
https://en.wikipedia.org/wiki/Waldenström_macroglobulinemia
Julius YoungnerJulius Youngner
From Youngner's work, formalin application for six days was projected to produce only "one live virus particle in 100 million ... Youngner was an important early pioneer in vaccine development, testing, and government licensing of drugs before allowing them ... Meulen, V. ter; Katz, M. (2013-11-11). Slow Virus Infections of the Central Nervous System: Investigational Approaches to ... developed by Youngner for safely and quickly testing batches of vaccine and also antibodies to the virus after application were ...
https://en.wikipedia.org/wiki/Julius_Youngner
TropoflavinTropoflavin
List of investigational antidepressants Tropomyosin receptor kinase B § Agonists US application 20150274692, Keqiang Ye, "7,8- ... Drugs missing an ATC code, Drugs with no legal status, Articles containing unverified chemical infoboxes, Antidepressants, ... Articles with short description, Short description matches Wikidata, ECHA InfoCard ID from Wikidata, Infobox drug articles with ... CNS Neurol Disord Drug Targets. 12 (7): 1066-77. doi:10.2174/18715273113129990089. PMID 23844685. Liu X, Chan CB, Jang SW, ...
https://en.wikipedia.org/wiki/Tropoflavin
RasagilineRasagiline
Teva Pharmaceutical". Current Opinion in Investigational Drugs. 3 (5): 794-7. PMID 12090555. Eisai Press Release. May 15, 2003 ... Teva and Technion filed patent applications for this racemically pure compound, methods to make it, and methods to use it to ... "Rasagiline". Drug Information Portal. U.S. National Library of Medicine. "Rasagiline mesylate". Drug Information Portal. U.S. ... The Organic Chemistry of Drug Design and Drug Action, 3rd Edition. Academic Press, 2014 ISBN 9780123820310 Cho HU, Kim S, Sim J ...
https://en.wikipedia.org/wiki/Rasagiline
PDE4BPDE4B
Current Opinion in Investigational Drugs. 10 (11): 1236-42. PMID 19876791. Moustafa F, Feldman SR (May 2014). "A review of ... possibly supporting further therapeutic applications. AN2728, a boron-containing drug candidate that as of 2015 was under ... 2011). Phosphodiesterases as Drug Targets (PDF). Handbook of Experimental Pharmacology. Vol. 204. Springer Berlin Heidelberg. ... to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs". ...
https://en.wikipedia.org/wiki/PDE4B
Pharmaceutical industryPharmaceutical industry
The firm continued to pressure Kelsey and the FDA to approve the application until November 1961, when the drug was pulled off ... This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support ... Drug discovery is the process by which potential drugs are discovered or designed. In the past, most drugs have been discovered ... Phase of clinical research in medicine Drug development - Process of bringing a new pharmaceutical drug to the market Drug ...
https://en.wikipedia.org/wiki/Pharmaceutical_industry
CompoundingCompounding
... investigational new-drug application Receiving, storing, or using drug substances without first obtaining written assurance ... The drug does not appear on the FDA list of drugs or categories of drugs that present "demonstrable difficulties" for ... if a monograph exists The drug does not appear on a list published by FDA of unsafe or ineffective drugs The drug is not " ... In the Drug Quality and Security Act (DQSA) of 2013 (H.R. 3204), Congress amended the Federal Food, Drug, and Cosmetic Act ( ...
https://en.wikipedia.org/wiki/Compounding
FirazorextonFirazorexton
Orexin receptor § Agonists List of investigational sleep drugs § Orexin receptor agonists "International Nonproprietary Names ... Proposed INN: List 123 WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, ... Drugs missing an ATC code, Drugs with no legal status, Articles containing unverified chemical infoboxes, Alcohols, ... Experimental drugs, Fluoroarenes, Orexin receptor agonists, Pyrrolidines, Sulfonamides, All stub articles, Nervous system drug ...
https://en.wikipedia.org/wiki/Firazorexton
Mark SchlisselMark Schlissel
... of Michigan faculty to accelerate drug candidates from laboratory investigations through their Investigational New Drug ... Two years after starting the Go Blue Guarantee, the University of Michigan saw a 10% increase in applications from Michigan ... Karoub, Jeff (May 27, 2020). "Deerfield commits up to $130M to commercialize drug discovery at the University of Michigan". ...
https://en.wikipedia.org/wiki/Mark_Schlissel
Clinical trialClinical trial
"Investigational New Drug (IND) Application - Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug ... All drug and many device trials target a subset of the population, meaning not everyone can participate. Some drug trials ... Patients whose genomic profiles do not match any of the trial drugs receive a drug designed to stimulate the immune system to ... Emanuel EJ (9 September 2015). "The Solution to Drug Prices". The New York Times. Of the drugs started in clinical trials on ...
https://en.wikipedia.org/wiki/Clinical_trial
EmricasanEmricasan
... an investigational drug targeting caspases and caspase-like proteases: the clinical trials in sight and recent anti- ... and its novel mechanism of action has led to research using it for other potential applications. McCallister E (Aug 9, 2010). " ... Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals. The drug was acquired by Pfizer ... October 2016). "Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug ...
https://en.wikipedia.org/wiki/Emricasan
TesofensineTesofensine
Lancet 2008;372:1906-13" (PDF). Expert Opinion on Investigational Drugs. 18 (7): 1043-6. doi:10.1517/13543780902967632. PMID ... and was subsequently dropped from development for these applications after early trial results showed limited efficacy for ... "Role of the increased noradrenergic neurotransmission in drug self-administration". Drug and Alcohol Dependence. 82 (2): 151-7 ... This is approximately twice the weight loss produced by medications currently approved by the US Food and Drug Administration ( ...
https://en.wikipedia.org/wiki/Tesofensine
Light therapyLight therapy
Patients on certain drugs such as methotrexate or chloroquine should use caution with light therapy as there is a chance that ... Terman M (December 2007). "Evolving applications of light therapy". Sleep Med Rev. 11 (6): 497-507. doi:10.1016/j.smrv.2007.06. ... Cosmetic and Investigational Dermatology. 8: 511-20. doi:10.2147/CCID.S87987. PMC 4599569. PMID 26491366. "Light Therapy". ... Light therapy is a mood altering treatment, and just as with drug treatments, there is a possibility of triggering a manic ...
https://en.wikipedia.org/wiki/Light_therapy
TIK-301TIK-301
In July 2007, the open Investigational New Drug (IND) was transferred to Tikvah Therapeutics Inc. in Atlanta, GA by Phase II ... Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G (2008). "Melatonin receptor agonists: SAR and applications to the treatment of ... Acquires Drug in Clinical Development to Treat Sleep Disorders". Phase 2 Discovery, Inc. Acquires Drug in Clinical Development ... In 2004, TIK-301 was designated an orphan drug by the FDA. In 2005, TIK-301 was expected to go into phase III trials. TIK-301 ...
https://en.wikipedia.org/wiki/TIK-301
TezampanelTezampanel
Eli Lilly & Co". Current Opinion in Investigational Drugs. 2 (9): 1273-8. PMID 11717815. Ornstein PL, Arnold MB, Augenstein NK ... Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific ... Drugs not assigned an ATC code, Drugs with non-standard legal status, Articles with changed ChemSpider identifier, Articles ... Tezampanel (INN, USAN) (code names LY-293,558, NGX-424) is a drug originally developed by Eli Lilly which acts as a competitive ...
https://en.wikipedia.org/wiki/Tezampanel
LenzilumabLenzilumab
Drugs with no legal status, Articles containing unverified chemical infoboxes, Drugs that are a monoclonal antibody, All ... Prior to application in treating CMML, lenzilumab was assessed for use in treating inadequately controlled asthma and ... "Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene ... Articles with short description, Short description matches Wikidata, Drugs not assigned an ATC code, Chemicals that do not have ...
https://en.wikipedia.org/wiki/Lenzilumab
MelatoninMelatonin
Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and ... Maestroni GJ (March 2001). "The immunotherapeutic potential of melatonin". Expert Opinion on Investigational Drugs. 10 (3): 467 ... Melatonin is sold as a dietary supplement in countries where it is not a scheduled drug. In the US, melatonin is considered a ... Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A (June 2016). "A Review of Melatonin, Its Receptors and Drugs". The ...
https://en.wikipedia.org/wiki/Melatonin
RVSV-ZEBOV vaccineRVSV-ZEBOV vaccine
In September 2019, the U.S. Food and Drug Administration (FDA) accepted Merck's Biologics License Application and granted ... "FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational ... Drugs with non-standard legal status, Chemicals that do not have a ChemSpider ID assigned, Infobox drug articles with non- ... The application for Ervebo in the United States was granted priority review, a tropical disease priority review voucher, and ...
https://en.wikipedia.org/wiki/RVSV-ZEBOV_vaccine
Melatonin as a medication and supplementMelatonin as a medication and supplement
Atkin T, Comai S, Gobbi G (April 2018). "Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and ... Expert Opinion on Investigational Drugs. 15 (4): 367-75. doi:10.1517/13543784.15.4.367. PMID 16548786. S2CID 28114683. Evers S ... Drug has EMA link, Drugboxes which contain changes to watched fields, Drugs that are a physiological drug, All articles with ... Drugs with non-standard legal status, Infobox drug articles with non-default infobox title, Infobox drug articles with ...
https://en.wikipedia.org/wiki/Melatonin_as_a_medication_and_supplement
LeronlimabLeronlimab
PRO140 has no multi-drug resistance or toxicities. Leronlimab, a monoclonal antibody investigational drug under development by ... In 2020 CytoDyn submitted a fast-track biologics license application for treatment of CCR5-tropic HIV-1 Infection. PRO 140 is ... Infobox drug articles with non-default infobox title, Articles without InChI source, Drugs with no legal status, Drugs that are ... The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug ...
https://en.wikipedia.org/wiki/Leronlimab
Transgender rights in the United StatesTransgender rights in the United States
In order to change the gender marker, one only needs to fill out a new drivers license/ID card application reflecting the ... "Anti-LGBTQ threats, fueled by internet's far right 'machine,' shut down trans rights and drag events". NBC News. Owen, Greg. " ... "experimental and investigational". The report was quickly rebuffed by the wider scientific community, with experts from Yale in ... Eckert, Jared (April 1, 2021). "Arkansas Bill Would Bar Doctors From Transgender Drug, Surgical "Experimentation" on Minors". ...
https://en.wikipedia.org/wiki/Transgender_rights_in_the_United_States
LatrepirdineLatrepirdine
Research was conducted in both Russia and western nations into potential applications as a neuroprotective drug to treat ... the investigational Alzheimer's disease drug dimebon failed in the pivotal CONNECTION trial of patients with mild-to-moderate ... Russian drugs, Soviet inventions, Drugs in the Soviet Union, Gamma-Carbolines). ... Novel Alzheimer's Drug Flops, MedPage Today, March 03, 2010 Sweetlove M: Phase III CONCERT Trial of Latrepirdine. Negative ...
https://en.wikipedia.org/wiki/Latrepirdine
Metachromatic leukodystrophyMetachromatic leukodystrophy
In the United States, an Investigational New Drug application for atidarsagene autotemcel was accepted by the Food and Drug ... Biomarin South (formerly Zacharon before being acquired by Biomarin in January 2013) from San Diego had initiated a drug ... This approach differs from other approaches which have measured enzyme activity to discover effective drugs.) As of July 2011, ... "Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD) , Orchard ...
https://en.wikipedia.org/wiki/Metachromatic_leukodystrophy
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of...Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of...
Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted CancersNov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. ( ... Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. ... Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of ... today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( ...
https://www.rttnews.com/pr/3265819/mirati-therapeutics-announces-submission-of-investigational-new-drug-application-to-u-s-food-and-drug-administration-of-mrtx1719-to-treat-mtap-deleted-cancers.aspx
A New Product (VariZIG ) for Postexposure Prophylaxis of Varicella Available Under an Investigational New Drug Application...A New Product (VariZIG ) for Postexposure Prophylaxis of Varicella Available Under an Investigational New Drug Application...
... became available under an investigational new drug application (IND) submitted to the Food and Drug Administration (FDA).* This ... A New Product (VariZIG ) for Postexposure Prophylaxis of Varicella Available Under an Investigational New Drug Application ... How to Obtain Investigational VariZIG Investigational VariZIG is produced by Cangene Corporation (Winnipeg, Canada) and is ... Investigational VariZIG is supplied in 125-U vials. The recommended dose is 125 units/10 kg body weight, up to a maximum of 625 ...
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a5.htm
Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen...Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen...
Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ... Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen ... submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single ... The SOF/VEL/VOX fixed-dose combination is an investigational product and its safety and efficacy have not been established. It ...
https://www.businesswire.com/news/home/20161208005609/en/
FDA Accepts New Drug Applications for Mercks Doravirine, the Companys Investigational Non-Nucleoside Reverse Transcriptase...FDA Accepts New Drug Applications for Merck's Doravirine, the Company's Investigational Non-Nucleoside Reverse Transcriptase...
FDA Accepts New Drug Applications for Mercks Doravirine, the Companys Investigational Non-Nucleoside Reverse Transcriptase ... accepted for review two New Drug Applications (NDAs) for doravirine, the. companys investigational non-nucleoside reverse ... for both applications under the Prescription Drug User Fee Act (PDUFA). "Since the earliest days of the epidemic, Merck has ... with the FDA as it reviews our applications." The NDAs are based upon the findings at Week 48 of two ongoing Phase 3. trials, ...
https://www.merck.com/news/fda-accepts-new-drug-applications-for-mercks-doravirine-the-companys-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-treatment-of-hiv-1-infection/
FDA Reviewing Investigational New Drug Application For 5 Year Old Twins Stricken With Fatal Cholesterol Disorder | The Addi and...FDA Reviewing Investigational New Drug Application For 5 Year Old Twins Stricken With Fatal Cholesterol Disorder | The Addi and...
I have always believed there would be a drug sitting on shelf somewhere that could help save the lives of our 5 year old twin ... FDA Reviewing Investigational New Drug Application For 5 Year Old Twins Stricken With Fatal Cholesterol Disorder. December 28, ... Tags: Childhood Alzheimers, CHORI, Cyclodextrin, FDA, Febreze, Investigational New Drug Application, Niemann Pick Type C ... You are here: Home / Cyclodextrin / FDA Reviewing Investigational New Drug Application For 5 Year Old Twins Stricken With Fatal ...
http://addiandcassi.com/fda-reviewing-application-to-give-cyclodextrin-sugar-compound-to-5-year-old-twins-stricken-with-fatal-cholesterol-disorder/comment-page-2/
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab | Kiniksa PharmaceuticalsKiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab | Kiniksa Pharmaceuticals
... today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration. (. FDA. ) for ... drug substance and/or drug product shortages; and our reliance on third parties to conduct our research, pre-clinical studies, ... Mavrilimumab is an investigational fully-human monoclonal antibody that is designed to antagonize GM-CSF signaling by binding ...
https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-active-us-investigational-new-drug-application/
Investigational New Drug CDMO Market Report, 2028Investigational New Drug CDMO Market Report, 2028
The global investigational new drug CDMO market size was valued at USD 4.2 billion in 2020 and is expected to expand at a ... Market revenue estimates and forecasts up to 2028, by application. *Market revenue estimates and forecasts up to 2028, by type ... Investigational New Drug CDMO Market Report, 2028. Investigational New Drug CDMO Market Size, Share & Trends Analysis Report By ... Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the ...
https://www.grandviewresearch.com/industry-analysis/investigational-new-drug-cdmo-market-report/methodology
Investigational New Drug (IND) Application FDA - Ensuring Safety and EffectivenessInvestigational New Drug (IND) Application FDA - Ensuring Safety and Effectiveness
Drug discovery is the process of discovering a new molecule and bringing it to the sector or public. Discovering a new molecule ... tagging: IND FDA > IND investigational new drug > Investigational New Drug > investigational new drug application ... Investigational New Drug (IND) Application FDA - Ensuring Safety and Effectiveness. By Harry 06/18/2021 Category: Other Blogs. ... The results of a new medication have to be provided to the Investigational New Drug (IND) Application FDA to gain approval and ...
https://biotechresearchgroup.com/investigational-new-drug-ind-application-fda/
Ophthalmology 360 | FDA accepts investigational new drug application for dry eye dropOphthalmology 360 | FDA accepts investigational new drug application for dry eye drop
The U.S. Food and Drug Administration (FDA) accepted an investigational new drug application for AR-15512 (Aerie ... FDA accepts investigational new drug application for dry eye drop. Posted on ...
https://ophthalmology360.com/dry-eye/fda-accepts-investigational-new-drug-application-dry-eye-drop/
NYSE:COTY | Stock Discussion | Coty Inc. Class ANYSE:COTY | Stock Discussion | Coty Inc. Class A
FSD Pharma Files Investigational New Drug Application "IND". posted June 02, 2022 12:03 am by KennyH * View Profile ... FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in ... Regulatory Advisory Board will oversee the drug development...read more ...
https://stockhouse.com/companies/bullboard?symbol=coty
HTA 101: GlossaryHTA 101: Glossary
Investigational New Drug Application (IND): an application submitted by a sponsor to the US FDA prior to human testing of an ... New Drug Application (NDA): an application submitted by a sponsor to the FDA for approval to market a new drug (a new, ... Investigational Device Exemption (IDE): a regulatory category and process in which the US Food and Drug Administration (FDA) ... Drug compendium: a comprehensive listing or index of summary information about drugs and biologicals (or a subset of these, e.g ...
https://www.nlm.nih.gov/nichsr/hta101/ta101013.html
Biostage - Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™...Biostage - Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™...
Food and Drug Administration (FDA) related to the Companys Investigational New Drug (IND) application for the Cellspan ... Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan™ Esophageal ... Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved ...
https://biostage.com/investors/press-releases/for-single-press-styling/press-2020/biostage-provides-update-on-fda-investigational-new-drug-application-for-its-lead-product-candidate-cellspan-tm-esophageal-implant
PharmaCyte Biotechs Release Testing Last Critical Event Before Submission of Investigational New Drug Application - Stock...PharmaCyte Biotech's Release Testing Last Critical Event Before Submission of Investigational New Drug Application - Stock...
PharmaCyte Biotechs Release Testing Last Critical Event Before Submission of Investigational New Drug Application ... Home News Features PharmaCyte Biotechs Release Testing Last Critical Event Before Submission of Investigational New Drug ... items to just one last important component-release testing-before it can submit an Investigational New Drug application (IND) ... PharmaCytes IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, ...
https://www.stockmarketmediagroup.com/pharmacyte-biotechs-release-testing-last-critical-event-before-submission-of-investigational-new-drug-application/
Early Release - Enhanced Adenovirus Vaccine Safety Surveillance in Military Setting, United States - Volume 29, Number 6-June...
US Food and Drug Administration. CFR-Code of Federal Regulations Title 21, 21CFR312.32. Investigational new drug application [ ... Adenovirus infection results in considerable illness among congregate military populations (1). US Food and Drug Administration ... measured vaccine uptake and inability to swallow pills and monitored cadets for 90 days after vaccination for US Food and Drug ...
https://wwwnc.cdc.gov/eid/article/29/6/23-0331_article
PGY-2 Medication-Use Safety & Policy | Memorial Sloan Kettering Cancer CenterPGY-2 Medication-Use Safety & Policy | Memorial Sloan Kettering Cancer Center
Investigational Drug Service [longitudinal] * Material Management: Supply chain, drug shortage management, narcotic ... Medication Event Analysis [longitudinal]: Dissect and trend actual and close-call events; appropriate application of health ... The resident will also learn about the medication use challenges in one of the worlds most extensive investigational drug ... Director, Drug Policy Management, Quality, Safety, Training and Education. Medication-Use Safety and Policy PGY-2 Residency ...
https://www.mskcc.org/hcp-education-training/residencies/pgy-2-medication-use-safety
AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of...AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of...
AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of ... AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of ... AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of ... www.Prnewswire.Com/information-releases/abbvie-submits-new-drug-application-to-us-fda-for-investigational-abbv-951- ...
https://comwikipedia.org/2022/05/21/abbvie-submits-new-drug-application-to-u-s-fda-for-investigational-abbv-951-foscarbidopa-foslevodopa-for-the-treatment-of-advanced-parkinsons-disease/
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP...Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP...
... of the Investigational New Drug (IND) application for Napos NP-300, a novel drug product candidate for the symptomatic relief ... Subsidiary-Napo-Pharmaceuticals-Announces-Activation-by-FDA-of-Investigational-New-Drug-IND-Application-for-NP-300-a-Novel-Drug ... Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP- ... Upon completion of the requisite development activities to support the New Drug Application (NDA) and subsequent approval of NP ...
https://www.detroitstar.com/news/272809780/jaguar-health-subsidiary-napo-pharmaceuticals-announces-activation-by-fda-of-investigational-new-drug-ind-application-for-np-300-a-novel-drug-candidate-for-the-symptomatic-relief-and-treatment-of-diarrhea-from-cholera-and-other-pathogens
Clinical Management and Research Support | HematologyClinical Management and Research Support | Hematology
Investigational New Drug (IND) application. *Study closure. Subject Management *Eligibility. *Subject recruitment ...
https://www.cincinnatichildrens.org/research/divisions/h/hematology/clinical-management-research-support
ARCHIVED - Veterinary Drugs Directorate Health Products and Food Branch Health Canada - Strategic Plan - Canada.caARCHIVED - Veterinary Drugs Directorate Health Products and Food Branch Health Canada - Strategic Plan - Canada.ca
Supplemental Abbreviated New Drug Submissions (SABNDS). *Drug Identification Number Applications (DIN). *Investigational New ... Under the Canadian Food and Drugs Act and Regulations (F&DA), manufacturers who wish to sell veterinary drugs in Canada must ... Receiving and evaluating Adverse Drug Reaction (ADR) reports from drug sponsors, manufacturers, health care practitioners, ... which take into account national and international safety data from drug sponsors on targeted classes of drugs; and ...
https://www.canada.ca/en/health-canada/corporate/about-health-canada/reports-publications/health-products-food-branch/veterinary-drugs-directorate-strategic-plan-april-2005-march-2008.html
China FDA Solicits Comments on Conditional Approvals for New Drugs and Compassionate Use of Investigational Drugs | Ropes &...China FDA Solicits Comments on Conditional Approvals for New Drugs and Compassionate Use of Investigational Drugs | Ropes &...
For any new drug applications ("NDA") that may be eligible for conditional approvals, the applicant may apply for a meeting ... The clinical studies of the investigational drug were completed, but the investigational drug has not been marketed in China; ... China FDA Solicits Comments on Conditional Approvals for New Drugs and Compassionate Use of Investigational Drugs December 27, ... When patients do not meet the enrollment criteria, they may take the investigational drugs through compassionate use. ...
https://www.ropesgray.com/en/newsroom/alerts/2017/12/China-FDA-Solicits-Comments-on-Conditional-Approvals-for-New-Drugs
Colorado: Health Officials Recommend $7.5 Million In Grant Funding For Clinical Cannabis Trials - NORMLColorado: Health Officials Recommend $7.5 Million In Grant Funding For Clinical Cannabis Trials - NORML
IND-Investigational New Drug application;FDA) ... In fact, the study goes so far as to suggest the entire drug ... The greatest threat to American safety and health today is the Controlled Substances Act and the Office of National Drug ... overcrowded drug and disease infested prisons. Among those laws? Providing food stamps, jobs and health care to those returning ... prison and drug reform to pass through Congress; which eventually does have to happen, regardless of Obamas potential ...
https://norml.org/blog/2014/11/26/colorado-health-officials-recommend-7-5-million-in-grant-funding-for-clinical-cannabis-trials/
Acute Cutaneous Lupus Erythematosus (ACLE) Treatment & Management: Approach Considerations, Precautions in Corticosteroid Use,...Acute Cutaneous Lupus Erythematosus (ACLE) Treatment & Management: Approach Considerations, Precautions in Corticosteroid Use,...
Investigational Drugs. Epratuzumab is an investigational drug. It is a humanized anti-CD22 monoclonal antibody that partially ... and daily application of broad-spectrum sunscreens. [38] ... New immunomodulating drugs such as iberdomide, a derivative of ... Lenalidomide (analogue of thalidomide) is an immunomodulatory drug with antineoplastic, anti-inflammatory, and antiangiogenic ...
https://emedicine.medscape.com/article/1065292-treatment
Overview of Lynparza: Treatment for ovarian cancerOverview of Lynparza: Treatment for ovarian cancer
Read on to explore the clinical trial approval process, how this drug is prescribed, and the possible side effects. ... application. to the FDA with a plan to test the drug on humans. This application is an Investigational New Drug (IND) ... drugs before they reach the market.. The drug manufacturer develops the drug and tests it on animals to check its toxicity. ... application.. After review and approval of the IND application by the FDA, the drug manufacturer can begin clinical trials, ...
https://www.medicalnewstoday.com/articles/lynparza-for-the-treatment-of-ovarian-cancer
Clinical research - WikipediaClinical research - Wikipedia
are submitted in support of an Investigational New Drug (IND) application[4] to the FDA for review prior to conducting studies ... FDA Page last updated 27 October 2014 Investigational New Drug (IND) Application ... "The Drug Development Process; Step 3: Clinical Research". US Food and Drug Administration. 4 January 2018. Retrieved 28 June ... Clinical trials involving new drugs are commonly classified into four phases.[6] Each phase of the drug approval process is ...
https://en.wikipedia.org/wiki/Clinical_research
Investigational CBD Product for Easing Pain After Shoulder SurgeryInvestigational CBD Product for Easing Pain After Shoulder Surgery
... carefully scrutinized product under an investigational new drug application sanctioned by" the U.S. Food and Drug ... Pleasedo not use this form to submit personal or patient medical information or to report adverse drug events. You are ... NEW YORK (Reuters Health) - An investigational, orally absorbed cannabidiol (CBD) product effectively reduced pain after ...
http://www.medscape.com/viewarticle/971020
Drug Makers File With European Medicines Agency For Regulatory Approval Of Investigational Ebola Vaccine; WHO Notes Fluctuating...Drug Makers File With European Medicines Agency For Regulatory Approval Of Investigational Ebola Vaccine; WHO Notes Fluctuating...
... have submitted an application to the European Medicines Agency (EMA) for approval of their investigational two-dose Ebola ... Drug Makers File With European Medicines Agency For Regulatory Approval Of Investigational Ebola Vaccine; WHO Notes Fluctuating ...
https://www.kff.org/news-summary/drug-makers-file-with-european-medicines-agency-for-regulatory-approval-of-investigational-ebola-vaccine-who-notes-fluctuating-pattern-of-disease-transmission-in-drc-outbreak/
Tuberculosis (TB) Treatment & Management: Approach Considerations, Treatment During Pregnancy, Treatment in ChildrenTuberculosis (TB) Treatment & Management: Approach Considerations, Treatment During Pregnancy, Treatment in Children
Clofazimine (available only through Investigational New Drug application through FDA) * Cycloserine * An aminoglycoside: ... Drug therapy. For initial empiric treatment of TB, start patients on a 4-drug regimen: isoniazid, rifampin, pyrazinamide, and ... Antituberculosis drug resistance in the world. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance ... However, if treatment is initiated, at least 2 drugs should be given, and the index isolate should be susceptible to all drugs ...
https://emedicine.medscape.com/article/230802-treatment
Investigational Drugs - BakerInvestigational Drugs - Baker
Applications & Solutions Applications. *Animal Science and Research. *Aseptic Biopharmaceutical Processing. *Biosafety and ...
https://bakerco.com/investigational-drugs/
Edgar Filing: MEDICINOVA INC - Form 10-KEdgar Filing: MEDICINOVA INC - Form 10-K
Investigational New Drug) application for MN-001 (tipelukast) for the treatment of NASH with the FDA in 2015. The FDA ... Overview. In the U.S., drugs and drug testing are regulated by the FDA under the Federal Food, Drug and Cosmetic Act, or FDCA, ... We utilize the existing data in preparing Investigational New Drug Applications (INDs) or their foreign equivalents, and in ... During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA) or a 505(b)(2) NDA ...
https://markets.financialcontent.com/stocks/action/getedgarwindow?accesscode=156459017001547
Expanded Access: FDA Describes Efforts to Ease Application Process | FDAExpanded Access: FDA Describes Efforts to Ease Application Process | FDA
Today, were lifting another potential burden for physicians who apply to FDA to use an investigational drug to treat their ... FDA has a long history of supporting patient access to investigational new treatments. This includes working with drug and ... Weve seen some reluctance among companies to provide investigational drugs for expanded access. This may have been due, in ... We also offer expanded access programs that provide investigational drugs and devices to patients with serious conditions ( ...
https://www.fda.gov/news-events/fda-voices/expanded-access-fda-describes-efforts-ease-application-process
Small moleculeVaccineINDsInhibitorRegimenSubmissionVaccinesPatientsFirm'sApprovalGuidancePreclinicalWholesalersDevelopmentDiabetesTreatmentTherapeuticRegulatoryProduct2022AuthorizationPharmaceuticalsProductsProcessMetabolism2019FoodTherapyPrescription DruCriticalOccurs2018MedicationReceptorDiscoveryPharmacologyReviewFDA'sCenters2000Veterinary drugsPharmaceuticalEfficacy and safetyApprovalsEffectiveness2023Illness2020AdditionallyAdministrationSafetyDevicesStudyCompassionatePatient
Small molecule3
  • adagrasib (MRTX849), an investigational small molecule, potent and selective KRAS G12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib , an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. (rttnews.com)
  • The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. (wjbf.com)
  • The armamentarium for managing HCC is wide and includes surgical resection, orthotopic liver transplantation (OLT), ablative techniques using ethanol (percutaneous ethanol injection, PEI), microwave (MWA) or radiofrequency (RFA), catheter-directed transarterial chemoembolization (TACE) or radioembolization (TARE), external beam radiation therapy in the form of stereotactic body radiation therapy (SBRT) or proton beam therapy (PBT), systemic targeted small molecule tyrosine kinase inhibitors, check-point inhibitor immunotherapy and investigational agents. (intechopen.com)
Vaccine11
  • Any patient who receives investigational VariZIG to prevent varicella subsequently should receive varicella vaccine, provided the vaccine is not contraindicated. (cdc.gov)
  • US Food and Drug Administration-approved use of a live, oral, bivalent adenovirus vaccine for military populations began in 2011 and was associated with substantial decreases in adenovirus infection incidence at US military basic training centers ( 2 , 3 ). (cdc.gov)
  • We measured vaccine uptake and inability to swallow pills and monitored cadets for 90 days after vaccination for US Food and Drug Administration-defined serious adverse events ( 9 ). (cdc.gov)
  • Bavarian Nordic [Thursday] announced that it and its partner Janssen Pharmaceuticals, part of Johnson & Johnson, have submitted an application to the European Medicines Agency (EMA) for approval of their investigational two-dose Ebola vaccine regimen. (kff.org)
  • FDA has given the OK for use of the vaccine at Princeton University under an Investigational New Drug application. (cdc.gov)
  • The Centers for Disease Control and Prevention's (CDC) Drug Services provides smallpox vaccine to these recommended individuals as needed. (cdc.gov)
  • Aventis Pasteur Smallpox Vaccine (APSV) is an investigational vaccine that may be used in a smallpox emergency under the appropriate regulatory mechanism (i.e. (cdc.gov)
  • The U.S. Food and Drug Administration (FDA) has licensed ACAM2000® , (Smallpox [Vaccinia] Vaccine, Live), a replication-competent vaccine, for active immunization against smallpox disease in persons determined to be at high risk for smallpox infection. (cdc.gov)
  • It is an investigational vaccine. (cdc.gov)
  • If vaccine candidates are successful after this stage (few are), an application for an Investigational New Drug (IND) is submitted to the Food and Drug Administration. (diseasedaily.org)
  • As there is no vaccine, drug treatment is the only way to tackle leishmaniasis. (who.int)
INDs1
  • Over the course of his 30+ year career, he has generated more than 25 Investigational New Drugs (INDs) and achieved four product approvals. (wspa.com)
Inhibitor6
  • SAN DIEGO , Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company's synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase ( MTAP )-deleted cancers. (rttnews.com)
  • Mirati is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRAS G12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs. (rttnews.com)
  • It has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of chronic genotype 1 HCV patients who have previously failed an NS5A inhibitor-containing regimen. (businesswire.com)
  • SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors. (wjbf.com)
  • KO-2806 is a potent next-generation inhibitor of farnesyl transferase designed to improve upon potency, pharmacokinetic and physicochemical properties of earlier FTI drug candidates. (wjbf.com)
  • TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir . (drugbank.com)
Regimen5
  • FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV)-infected patients. (businesswire.com)
  • or compliance or concordance) a measure of the extent to which patients undergo, continue to follow, or persist with a treatment or regimen as prescribed, e.g., taking drugs, undergoing a medical or surgical procedure, doing an exercise regimen, or abstaining from smoking. (nih.gov)
  • Intended to increase the quality, speed, and efficiency of trials, adaptive trials typically involve interim analyses, changes to sample size, changes in randomization to treatment arms and control groups, and changes in dosage or regimen of a drug or other technology. (nih.gov)
  • For initial empiric treatment of TB, start patients on a 4-drug regimen: isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin. (medscape.com)
  • This woman was admitted to isolation and started empirically on a 4-drug regimen in the ED. Tuberculosis was confirmed on sputum testing. (medscape.com)
Submission7
  • Where devices are concerned the submission to the FDA would be for an Investigational Device Exemption (IDE) application if the device is a significant risk device or is not in some way exempt from prior submission to the FDA . (wikipedia.org)
  • In addition, clinical research may require Institutional Review Board (IRB) or Research Ethics Board (REB) and possibly other institutional committee reviews, Privacy Board, Conflict of Interest Committee, Radiation Safety Committee, Radioactive Drug Research Committee, etc. approval whether or not the research requires prior submission to the FDA. (wikipedia.org)
  • This page summarizes the clinical trial registration and results information submission requirements described in Section 801 of the Food and Drug Administration Amendments Act of 2007 (PDF), known as FDAAA 801. (clinicaltrials.gov)
  • Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. (nih.gov)
  • Biogen and Ionis today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of nusinersen , an investigational treatment for spinal muscular atrophy (SMA). (curesma.org)
  • NIH's new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. (nih.gov)
  • ASSIST replaces the Grants.gov downloadable forms currently used with most NIH opportunities and provides many features to enable electronic multi-project application submission and improve data quality, including: pre-population of organization and PD/PI data, pre-submission validation of many agency business rules and the generation of data summaries in the application image used for review. (nih.gov)
Vaccines3
  • There are useful discussions on the unique ethical issues raised by HIV infection and AIDS, by the asserted right of HIV-infected people to have access to incompletely tested new treatments, and by the prospect of field trials of candidate AIDS vaccines and drugs. (who.int)
  • Chapters also reflect a growing perception that research involving human subjects is beneficial rather than threatening and that vulnerable groups, such as women, children, the elderly, and prisoners, should not be deprived arbitrarily of the opportunity to benefit from investigational drugs, vaccines or devices. (who.int)
  • [ 1 ] Two mRNA monoclonal vaccines (Comirnaty by Pfizer and Spikevax by Moderna) gained full approval by the US Food and Drug Administration (FDA). (medscape.com)
Patients19
  • Patients without evidence of immunity to varicella (i.e., without history of disease or age-appropriate vaccination) who are at high risk for severe disease and complications, who have been exposed to varicella, and from whom informed consent has been obtained, are eligible to receive the IND application product under an expanded access protocol. (cdc.gov)
  • The resident will be prepared to assume a leadership position to implement sustained medication-use and quality improvement strategies and manage formulary and drug policies for adult and pediatric patients. (mskcc.org)
  • The resident will use our fully integrated electronic medical record with over 6000 order sets and a library of comprehensive drug guidelines for virtually all medications used in cancer patients. (mskcc.org)
  • Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. (detroitstar.com)
  • If adopted, these drafts are likely to streamline and accelerate the market access of new drugs and allow Chinese patients to have early access to innovative therapies. (ropesgray.com)
  • When patients do not meet the enrollment criteria, they may take the investigational drugs through compassionate use. (ropesgray.com)
  • the available research data can indicate the effectiveness and safety of the investigational drug on relevant patients. (ropesgray.com)
  • Patients with ACLE require extensive education about avoidance of sun exposure, photoprotection through physical barriers such as protective clothing, and daily application of broad-spectrum sunscreens. (medscape.com)
  • We also offer expanded access programs that provide investigational drugs and devices to patients with serious conditions (generally prior to product approval), when there is no therapeutic alternative. (fda.gov)
  • FDA recognizes that time is critical for these seriously ill patients who do not have alternative therapies, and who cannot take part in a clinical trial of an investigational therapy. (fda.gov)
  • Dedicated staff in the Office of Health and Constituent Affairs and CDER's Office of Communications, Division of Drug Information, already assist physicians and patients in navigating this system. (fda.gov)
  • Last month, Zydus Cadila had filed the investigational new drug application for ZYIL1, positioned for management of critically ill COVID-19 patients. (livemint.com)
  • The firm represents a wide range of clients on FDA regulatory matters including food, drug, and dietary supplement companies, scientists: physicians, patients: consumers and holistic and alternative practitioners. (emord.com)
  • MARLBOROUGH, Mass.--( BUSINESS WIRE )-- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist (LAMA), delivered via PARI's innovative investigational eFlow ® closed system nebulizer, for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). (businesswire.com)
  • We look forward to working with the FDA as we seek to gain approval of this innovative drug-device combination and further address the needs of patients with this debilitating condition. (businesswire.com)
  • AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. (genetherapynet.com)
  • Under the agreement, ITM will provide Endocyte with supply of n.c.a. 177 Lu for its investigational 177 Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer. (itm-radiopharma.com)
  • Pending approval of investigational drug candidate 177 Lu-PSMA-617, ITM would continue to provide its proprietary n.c.a. 177 Lu during the commercial phase, supporting the scalability and security-of-supply for patients world-wide. (itm-radiopharma.com)
  • We appreciate the FDA's collaboration with us during the application process, and we look forward to continuing this productive dialogue, with the goal of rapidly bringing the first treatment for SMA to as many patients as possible. (curesma.org)
Firm's4
  • The firm's FDA lawyers draft and file petitions, applications, comments, and requests for advisory opinions and stays to the agency. (emord.com)
  • The firm's broad regulatory practice touches upon myriad products ranging from Human Chorionic Gonadtropin (hCG), weight loss dietary supplements, over-thecounter drugs including hormone products, nutritional supplements, botanicals, and medical devices). (emord.com)
  • The firm's attorneys represent clients in constitutional and administrative law cases before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), the Drug Enforcement Administration (DEA), the Department of Justice (DOJ), the Department of the Interior, the Bureau of Land Management (BLM), the National Park Service (NPS), the Equal Employment Opportunity Commission, the Environmental Protection Agency (EPA), and the Federal Communications Commission (FCC). (emord.com)
  • Excision BioTherapeutics, Inc. IND Application for EBT-101 for HIV Accepted by the US FDA Excision BioTherapeutics, Inc., which focuses on developing CRISPR-based therapies intended to cure viral infectious diseases, announced that the U.S. FDA has accepted the firm's Investigational New Drug (IND) application for EBT-101 - a CRISPR-based therapeutic candidate in development as a potential functional cure for chronic HIV. (prohostbiotech.com)
Approval18
  • It takes regulatory approval to advertise the drug. (biotechresearchgroup.com)
  • The results of a new medication have to be provided to the Investigational New Drug (IND) Application FDA to gain approval and begin clinical trials in people. (biotechresearchgroup.com)
  • or progressive licensing) refers to proposals for prospectively planned, stepwise, and adaptive approaches to market approval for drugs, biologics, and other regulated technologies. (nih.gov)
  • For example, this would enable earlier approval (at phase II or even phase I) of a drug for narrowly defined indications while RCTs or other trials continue to generate confirmatory data, data for broader indications, or data in real-world settings that could be used to modify licensing. (nih.gov)
  • Upon completion of the requisite development activities to support the New Drug Application (NDA) and subsequent approval of NP-300 by the FDA for the symptomatic relief and treatment of diarrhea from cholera, the Company intends to pursue a Tropical Disease Priority Review Voucher ('TDPRV') under the FDA's financial incentive program to develop NP-300 for this indication. (detroitstar.com)
  • For an orphan drug that has been marketed in foreign counties, the NDA applicant can apply for conditional approval based on the foreign study data used to support the foreign marketing approval. (ropesgray.com)
  • The NDA applicant must submit an application to CDE for an approval regarding the expanded access study. (ropesgray.com)
  • After review and approval of the IND application by the FDA, the drug manufacturer can begin clinical trials , which involve testing the drug on humans. (medicalnewstoday.com)
  • Additionally, some drugs may obtain accelerated approval , where a drug receives early approval because it treats serious diseases and conditions more effectively than existing therapies. (medicalnewstoday.com)
  • [6] Each phase of the drug approval process is treated as a separate clinical trial . (wikipedia.org)
  • This includes working with drug and device companies through the clinical trial process that may lead to FDA approval of the treatment. (fda.gov)
  • SOLANA BEACH, Calif., Jan. 25, 2000 (PRIMEZONE) -- Situs Corp. today announced that it has received FDA approval to begin Phase 1-2 clinical testing of its intravesical drug delivery device, the. (globenewswire.com)
  • Data from such studies are considered by FDA in determining whether to grant or withhold approval of a drug product. (fda.gov)
  • Under the Act, a pharmaceutical manufacturer must apply to FDA for approval to market new drugs and is required to demonstrate, often through clinical trials, that a drug is safe and effective before receiving approval to market a drug. (fda.gov)
  • Emord & Associates assists clients with the animal drug approval process. (emord.com)
  • therefore, CDC received Investigational New Drug (IND) approval (BB-IND-7596) from the Food and Drug Administration. (cdc.gov)
  • For drug development , FDA approval of your Investigational New Drug (IND) application is the result of a successful drug development program, which begins with STILLMEADOW, Inc. (stillmeadow.com)
  • Any order placed online from a new customer, is subject to Monobind's approval, new account screening and application process. (monobind.com)
Guidance8
  • NP-300 is a novel oral botanical drug product that is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer, and is planned to be developed under the FDA's Botanical Guidance. (detroitstar.com)
  • As stated on the FDA's website , crofelemer is currently one of only two drugs that have been approved under the FDA's Botanical Guidance definition of a botanical drug product. (detroitstar.com)
  • To clarify how adverse event data in these circumstances are viewed, we've updated the guidance for industry entitled, 'Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers' (questions 25 and 26). (fda.gov)
  • The guidance clarifies that suspected adverse reactions must be reported "only if there is evidence to suggest a causal relationship between the drug and the adverse event. (fda.gov)
  • The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and protected time (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. (tulane.edu)
  • From guidance in the creation of unique pilot studies and protocols, to evaluation of the safety and efficacy of your product, STILLMEADOW, Inc.'s experienced study directors and laboratory technicians support your drug development in meeting FDA guidelines for advancement to clinical trials. (stillmeadow.com)
  • Revisions reflect the need for a fundamental rethinking of several principles embodied in the previous guidelines, which were issued in 1982 by CIOMS largely as guidance on the application to developing countries of the Declaration of Helsinki. (who.int)
  • The document also provides guidance on importing investigational products and exchanging and transferring biological specimens. (who.int)
Preclinical3
  • In drug development, preclinical research is the main stage of research which starts before the preclinical trials to accumulate the data of safety, testing and efficacy of this new drug. (biotechresearchgroup.com)
  • Clinical studies are, once the preclinical research has been completed, the company files an IND investigational new drug FDA (Food and Drug Administration) to obtain permission for testing in people. (biotechresearchgroup.com)
  • In addition, preclinical data is supportive of FTIs in combination with other targeted therapies to potentially overcome or prevent emergence of drug resistance to certain classes of drugs. (wjbf.com)
Wholesalers1
  • Pricing and Content Information Monobind Inc. services many markets and customers, including end-users, distributors and other wholesalers worldwide while providing e-commerce applications. (monobind.com)
Development22
  • We are excited to take this next step in the advancement of MRTX1719 to clinical trials," said James Christensen , Ph.D. , chief scientific officer, Mirati Therapeutics, Inc. "MRTX1719 was discovered and developed internally at Mirati, representing an important milestone for the Company's continued expansion of its pipeline and further reinforcing our differentiated end-to-end drug discovery and development capabilities. (rttnews.com)
  • Any statement describing Mirati's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati's drug development pipeline, including without limitation adagrasib (MRTX849), sitravatinib , MRTX1719 and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. (rttnews.com)
  • HAMILTON, Bermuda , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration ( FDA ) for a clinical study of mavrilimumab in subjects with giant cell arteritis (GCA). (kiniksa.com)
  • Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. (grandviewresearch.com)
  • Drug development is the practice of bringing a new product to the market. (biotechresearchgroup.com)
  • The program offers a diverse experience designed to develop the resident's skills in medication safety principles, leadership, process improvement, drug information, institutional policy development, planning, and research. (mskcc.org)
  • SOLANA BEACH, Calif., Nov. 2, 1999 (PRIMEZONE) -- Situs Corp., a leader in the development of alternate drug delivery systems, today announced it has filed an Investigational New Drug Application. (globenewswire.com)
  • SOLANA BEACH, Calif., Oct. 25, 1999 (PRIMEZONE) - Situs Corp., a leader in the development of alternate drug delivery systems, today announced the appointment of Malcolm Heaven as Chief Technology. (globenewswire.com)
  • Manufacturing process development and investigational new drug application-enabling studies are currently underway. (dailyfreeman.com)
  • DEERFIELD, Ill., November 1, 2011 - Takeda Global Research & Development Center, Inc., (Takeda) announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 25, 2012 for the review of its investigational type 2 diabetes therapy alogliptin, and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet. (takeda.com)
  • This course is intended as part 1 of a series: Drug Discovery, Drug Development (https://www.coursera.org/learn/drug-development) and Drug Commercialization (https://www.coursera.org/learn/drug-commercialization). (coursera.org)
  • HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider supporting small and medium pharma and biotech companies with its exceptional expertise spanning the complete pharmaceutical value chain from drug discovery to clinical development, marketing authorization and market access, today announced the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. (yourerie.com)
  • VPM has supported our drug development from the very start, throughout Phase I, and helped us to conclude our trial efficiently, cost-effectively and successfully. (yourerie.com)
  • Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. (cdc.gov)
  • Currently, with many venom-derived peptides undergoing different phases of clinical trials, more are in pre-clinical drug development phases. (bvsalud.org)
  • The National Institute of General Medical Sciences (NIGMS) invites applications for Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards from investigators at biomedical research institutions that award doctoral degrees in the health sciences or sciences related to health or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other Federal agencies within the IDeA eligible states. (nih.gov)
  • We have one FDA-approved precision therapy and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. (biospace.com)
  • Our dose testing services specialists have provided full-service, lab-certified evaluations since 1975 in the areas of drug development, mammalian and environmental toxicology, animal health, entomology, analytical services, and in vitro studies. (stillmeadow.com)
  • Novoheart is a subsidiary fully owned by Medera Two new Pfizer-coauthored studies validate Novoheart's pioneering human bioengineered heart tissues and chambers for improving drug development Novoheart seeks to revolutionize human heart tissue engineering for disease. (medera.bio)
  • Propolis: Is there a potential for the development of new drugs? (blogspot.com)
  • Since propolis-containing products have been marketed and humans have used propolis for different purposes, the goal of this review is to discuss the potential of propolis for the development of new drugs, by comparing data from the literature that suggest candidate areas for the establishment of drugs against tumors, infections, allergy, diabetes, ulcers and with immunomodulatory action. (blogspot.com)
  • ZURICH, SWITZERLAND / ACCESSWIRE / January 24, 2023 / InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces the appointment of Dr. Christopher Prior as Chief Executive Officer. (wspa.com)
Diabetes1
  • Despite the advent of effective antiviral drugs to eradicate hepatitis C infection, the prevalence of HCC is projected to increase secondary to increasing rates of fatty liver disease from diabetes and the obesity epidemic [ 2 ]. (intechopen.com)
Treatment10
  • Doravirine (MK-1439, DOR) is an investigational NNRTI being evaluated by Merck for the treatment of HIV-1 infection. (merck.com)
  • However, we're not asking for a "drug" treatment like chemotherapy - this sugar compound has an excellent safety profile and is non-toxic. (addiandcassi.com)
  • ABBV ) today introduced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in sufferers with advanced Parkinson's disease (PD). (comwikipedia.org)
  • As part of a plan to simplify the process for physicians seeking access to an investigational product to treat their patient, I'm announcing today that just one IRB member - the chair or another appropriate person - can now approve the treatment. (fda.gov)
  • Dr. Koob reported the deaths of two noted scientists: Richard Saitz, M.D., M.P.H., who made significant contributions to the alcohol prevention and treatment field, and John Spitzer, M.D., whose legacy includes the Louisiana State University Health Sciences Center (LSUHSC) Comprehensive Alcohol Research Center and the LSUHSC Alcohol and Drug Abuse Center of Excellence. (nih.gov)
  • Scientists should consider efficiency and how quickly they can achieve those high numbers, as the quality and treatment value of MSCs diminishes over time, adds Ben Josey, Ph.D., a field application scientist at Corning Life Sciences. (corning.com)
  • The FDA sent it a complete response letter regarding its new drug application for an investigational medicine for the treatment of insomnia, suvorexant. (aol.com)
  • In October 2012, Takeda submitted a New Drug Application (NDA) for Cetilistat to Japan's Ministry of Health, Labour and Welfare for the treatment of obesity. (clinicaltrialsarena.com)
  • While these data support the NDA filing which has been accepted by the U.S. Food and Drug Administration (FDA), acceptance of the NDA does not mean that SUN-101/eFlow ® will be approved by the FDA for the treatment of adults with COPD. (businesswire.com)
  • The investigational combined product, consisting of SUN-101 and the eFlow ® closed system nebulizer which has been optimized for SUN-101 delivery, has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COPD. (businesswire.com)
Therapeutic3
  • Each week you will learn the steps that a pharmaceutical or biotech company goes through to discover a new therapeutic drug. (coursera.org)
  • Drugs contain ingredients with therapeutic activity, so-called "active ingredients" as well as inactive ingredients. (player.fm)
  • The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. (wspa.com)
Regulatory4
  • If the drug successfully passes through Phases I, II, and III, it will be approved by the national regulatory authority for use in the general population. (wikipedia.org)
  • Define and understand the regulatory responsibilities for drug discovery to file an Investigational New Drug Application (IND). (coursera.org)
  • An application that must be submitted to a regulatory agency (the FDA in the United States) before a drug can be studied in humans. (bvsalud.org)
  • When the application goes back to the sponsor with questions to prepare responses to the regulatory authority, the period of time during which the evaluation of a medicine is officially stopped. (who.int)
Product8
  • In February 2006, an investigational (not licensed) VZIG product, VariZIG (Cangene Corporation, Winnipeg, Canada) became available under an investigational new drug application (IND) submitted to the Food and Drug Administration (FDA). (cdc.gov)
  • Unlike the previous product, the investigational product is lyophilized. (cdc.gov)
  • The SOF/VEL/VOX fixed-dose combination is an investigational product and its safety and efficacy have not been established. (businesswire.com)
  • It's done when the last product or new compound is identified from the drug discovery process. (biotechresearchgroup.com)
  • Researchers also run the studies in cells and tissues to finalize the lead chemical that becomes a final product or medicine in the practice of drug discovery and growth. (biotechresearchgroup.com)
  • At the onset of these drugs' clinical experience using a fresh medicinal product or its usages, specifically, as the curative doses or dose may not be established, all unintended and toxic responses to the medicinal product associated with any of the does should be thought to be the adverse drug reaction. (biotechresearchgroup.com)
  • Before expanded access can occur, the drug company must decide whether or not to provide the product. (fda.gov)
  • This letter is to inform you that the Food and Drug Administration (FDA) is proposing to issue an order debarring you for a period of five years from providing services in any capacity to a person that has an approved or pending drug product application. (fda.gov)
20222
  • The company plans to file an Investigational New Drug Application in the first half of 2022 to begin human trials. (biospace.com)
  • Prescription drug prices lag inflation, according to new information from the Altarum November 2022 Health Sectors Economic Indicators Briefs. (cobioscience.com)
Authorization1
  • In addition to the NDA filing with FDA, Biogen plans to submit a Marketing Authorization Application (MAA) for nusinersen to the European Medicines Agency (EMA) in the coming weeks. (curesma.org)
Pharmaceuticals1
  • The U.S. Food and Drug Administration (FDA) accepted an investigational new drug application for AR-15512 ( Aerie Pharmaceuticals, Inc) for dry eye. (ophthalmology360.com)
Products9
  • Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. (rttnews.com)
  • Compassionate use of investigational products is regulated as if it were a clinical study, and can be deemed an expanded access study. (ropesgray.com)
  • A genre or grouping of drug products that all work in a similar way. (ipmglobal.org)
  • IPM's facility responsible for producing the products used in clinical trials, including the active drug and the placebo. (ipmglobal.org)
  • These clinical studies were being conducted to evaluate the safety and efficacy of drug products, and you were the principal investigator for these studies. (fda.gov)
  • Condition of Sales Under the U.S. Food and Drug Administration (FDA), several of the products available for purchase from Monobind are available for research uses only. (monobind.com)
  • The Code of Federal Regulations, Title 21, Sections 312.9 and 809.10 explicitly state that such research products are for investigational use in laboratory research animals or in-vitro research only. (monobind.com)
  • These guidelines are intended to define the stability data package for active substances and pharmaceutical products that is sufficient for a registration application within countries of the World Health Organization's Eastern Mediterranean Region [1]. (who.int)
  • The guidelines address the information to be submitted in applications for registration of New Chemical Entities as well as existing active substances and their related pharmaceutical products for human use. (who.int)
Process10
  • Drug discovery is the process of discovering a new molecule and bringing it to the sector or public. (biotechresearchgroup.com)
  • The Draft Conditional Approvals Guidelines propose the eligibility criteria and application process for conditional approvals. (ropesgray.com)
  • The Draft Compassionate Use Measures set forth the definition, the purposes, the criteria, and the application process. (ropesgray.com)
  • In an effort to eliminate potential hurdles that might delay or even discourage applications, FDA streamlined the expanded access process by introducing a new application form which a physician may use to request expanded access for their patient. (fda.gov)
  • In this course you will learn the drug discovery process up to the filing of an Initial New Drug Application or IND. (coursera.org)
  • In this course you will be able to: * Understand the pharmaceutical and biotechnology market a changing landscape * Learn the major aspects of the drug discovery process, starting with target selection, to compound screening to designing lead candidates. (coursera.org)
  • I truly appreciate the Drug process in entirety being broken down into sections that are easy to comprehend. (coursera.org)
  • After you determine your research qualifies as human subjects, it will help you decide what to include in your application and what other items to comply with before and during the application process. (nih.gov)
  • The document contains a detailed description of the emergency joint review process for clinical trial applications, including a discussion of the application process and stakeholders' roles and responsibilities. (who.int)
  • These timelines encompass the entire review process, from AVAREF's receipt of the clinical trial application to the joint review panel's final decision. (who.int)
Metabolism2
  • Are In Vitro Metabolism and Drug-Drug Interaction Studies Critical for an Investigational New Drug Application? (insidescientific.com)
  • It also turns out that PAG and PA are byproducts of the metabolism of a drug called phenylbutyrate (PB), that Burzynski has also been using off-label to treat all kinds of cancers . (scienceblogs.com)
20191
  • August 23, 2019 - Clarifying Competing Application Instructions and Notice of Publication of Frequently Asked Questions (FAQs) Regarding Proposed Human Fetal Tissue Research. (nih.gov)
Food12
  • HOLLISTON, Mass. , Jan. 2, 2020 / PRNewswire / -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, received the anticipated formal response from the U.S. Food and Drug Administration (FDA) related to the Company's Investigational New Drug (IND) application for the Cellspan Esophageal Implant (CEI). (biostage.com)
  • The China Food and Drug Administration ("CFDA") recently proposed two draft circulars for public comments, namely (a) the Technical Guidelines for Conditional Approvals for Urgently Needed Drugs ( "Draft Conditional Approvals Guidelines" ) and (b) the Administrative Measures for Compassionate Use of Investigational Drugs ("Draft Compassionate Use Measures") . (ropesgray.com)
  • To protect human and animal health and the safety of Canada's food supply, VDD evaluates and monitors the safety, quality and effectiveness, sets standards, and promotes the prudent use of veterinary drugs administered to food-producing and companion animals. (canada.ca)
  • The statutory requirements have been in effect since September 27, 2007, have been codified at section 402(j) of the Public Health Service (PHS) Act, and include conforming amendments to the Federal Food, Drug, and Cosmetic FD&C Act (FD&C Act). (clinicaltrials.gov)
  • The law firm has defeated the Food and Drug Administration (FDA) a remarkable seven times in federal court, five times on First Amendment grounds. (emord.com)
  • Emord is frequently consulted by media concerning the meaning and effect of regulations that have an impact on food, drug, and dietary supplement markets. (emord.com)
  • He regularly writes and lectures on issues pertaining to food, drug, and dietary supplement regulation. (emord.com)
  • The firm counsels clients on issues concerning pet food supplements, feed supplements, and animal drugs. (emord.com)
  • In 2004, Peplin submitted two Investigational New Drug Applications to the US Food and Drug Administration (FDA). (nhmrc.gov.au)
  • 3. Coverage required by this section shall include coverage for routine patient care costs incurred for drugs and devices that have been approved for sale by the Food and Drug Administration (FDA), regardless of whether approved by the FDA for use in treating the patient's particular condition, including coverage for reasonable and medically necessary services needed to administer the drug or use the device under evaluation in the clinical trial. (mo.gov)
  • Finally, we live in an age where the questions for analysis have broadened beyond the main issues confronting the U.S. Food and Drug Administration of 1954. (cdc.gov)
  • Find helpful information from the U.S. Food and Drug Administration about how to safely get rid of unused or expired medicine. (aetna.com)
Therapy3
  • Health professionals can use this data to determine whether a person would benefit from a particular drug or therapy. (medicalnewstoday.com)
  • Observational trial of the longitudinal effects of cystic fibrosis transmembrane reductance regulator (CFTR) modulator drugs - Prospectively identifying longitudinal changes in inflammation and sputum microbiology before and after CFTR modulator therapy. (nationaljewish.org)
  • BACKGROUND: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug reaction (ADR) commonly associated with bisphosphonate and denosumab therapy. (bvsalud.org)
Prescription Dru2
  • The FDA has set a target action date of Oct. 23, 2018, for both applications under the Prescription Drug User Fee Act (PDUFA). (merck.com)
  • The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is May 29, 2017. (businesswire.com)
Critical2
  • It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide , except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts ) and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. (nih.gov)
  • To our knowledge, no other AI approach to drug discovery addresses both cellular signaling and drug-target interaction, a critical link needed for effective drug discovery. (wspa.com)
Occurs1
  • This phase occurs after the drug enters the market, and its purpose is to investigate the safety and efficacy of the drug in a real-life setting. (medicalnewstoday.com)
20182
  • They estimate the drug could have sales of $700 million annually by 2018. (aol.com)
  • November 26, 2018 - NIH & AHRQ Announce Upcoming Updates to Application Instructions and Review Criteria for Research Grant Applications. (nih.gov)
Medication2
  • The most important advantage of generic medication is the cost, and frequently hospitals and physicians use generic drugs. (biotechresearchgroup.com)
  • Memorial Sloan Kettering (MSK) is pleased to offer a 12-month post-graduate training program that provides advanced training in medication-use safety, quality assessment, and drug policy. (mskcc.org)
Receptor2
  • Mavrilimumab is an investigational fully-human monoclonal antibody that is designed to antagonize GM-CSF signaling by binding to the alpha subunit of the GM-CSF receptor. (kiniksa.com)
  • The company is specialized in G Protein-Coupled Receptor (GPCR) drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan GPCRs. (wspa.com)
Discovery6
  • The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Discovery course brings you lectures from both faculty and industry experts. (coursera.org)
  • With this course, recorded on campus at UCSD, we seek to share our access to top people in the field who bring an unprecedented range of expertise on drug discovery. (coursera.org)
  • Recognize current modern drug discovery based on the lock-and-key theory, which attempts to use one single compound to hit one target to combat the related disease. (coursera.org)
  • Increase understanding of the various drug discovery tools and methods that are used for finding, identifying and designing a new drug. (coursera.org)
  • This course helps to understand the basic fundamental & principles of drug discovery clearly. (coursera.org)
  • This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. (wspa.com)
Pharmacology1
  • I am impressed with the advances the company has made in unlocking new drug targets with improved pharmacology", Dr. Prior noted. (wspa.com)
Review6
  • Just before Christmas, the FDA informed us of a 30 day hold on our application in order to review our case further. (addiandcassi.com)
  • We were very pleased to hear from the FDA that they have completed their review of our IND application for NP-300 and concluded that Napo may proceed with its proposed phase I clinical trial for the drug. (detroitstar.com)
  • The Council met in closed session from 11:00 a.m. to 11:30 a.m. for a presentation of the NIAAA Board of Scientific Counselors (AABSC) Report, and from 11:30 a.m.-12:32 p.m. to review grant applications and cooperative agreements. (nih.gov)
  • If you still have questions about whether your application has human subjects, ask your institutional review board (IRB) or independent ethics committee (IEC) before writing your application. (nih.gov)
  • Review of the 2010-2014 data identified several medications and drug classes associated with ONJ not previously described. (bvsalud.org)
  • The overarching goals of this final paper are to (1) review and summarize key information across contributions and (2) synthesize information to facilitate successful translation of otoprotective drugs from animal models into human application. (cdc.gov)
FDA's1
  • When submitted to FDA as part of a new drug application, these records are part of the basis for FDA's evaluation of the drug's safety and effectiveness, and FDA's determination as to whether the drug can be approved for marketing. (fda.gov)
Centers1
  • Collaborative Partnership between Research Centers in Minority Institutions (RCMI) and Alcohol Research Centers (U54, RFA-AA-21-015): This announcement invites U54 applications for the planning and implementation of collaborative partnerships between Research Centers in Minority Institutions (RCMI) and institutions with extensive alcohol research programs, including NIAAA-funded alcohol research centers and consortia. (nih.gov)
20003
  • ATLANTA, Ga. & SOLANA BEACH, Calif., April 30, 2000 (PRIMEZONE) --- Findings presented today at the 95th Annual American Urological Association Meeting show that a unique indwelling drug delivery. (globenewswire.com)
  • SOLANA BEACH, Calif., April 18, 2000 (PRIMEZONE) -- Situs Corporation, a pioneer in intravesical drug delivery, today announced it has received from the US Patent and Trademark Office notices of. (globenewswire.com)
  • SOLANA BEACH, Calif., Jan. 13, 2000 (PRIMEZONE) -- Situs Corp., a pioneer of intravesical drug delivery, today announced that its Chief Executive Officer, W. Tate Scott, has been appointed to the. (globenewswire.com)
Veterinary drugs3
  • The Veterinary Drugs Directorate ( VDD ) is a proactive public health organization that looks towards the future to anticipate potential opportunities and challenges, and develops viable plans to ensure that resources are used as efficiently and effectively as possible. (canada.ca)
  • The Veterinary Drugs Directorate Strategic Plan for 2005-2008 was approved by the VDD Management Committee on April 25, 2005. (canada.ca)
  • 1 As a Government of Canada organization, the fiscal year for the Veterinary Drugs Directorate extends from April 1 to March 31. (canada.ca)
Pharmaceutical3
  • In the United States, the FDA grants or denies the sale of drugs by pharmaceutical companies. (medicalnewstoday.com)
  • Before pharmaceutical companies start clinical trials on a drug, they conduct extensive pre-clinical studies . (wikipedia.org)
  • Data point out the importance of this research field not only for the readers and researchers in the scientific community waiting for further clarification on the potential of propolis but also for the pharmaceutical industry that looks for new drugs. (blogspot.com)
Efficacy and safety1
  • Phase II includes a larger number of individual participants in the range of 100-300, and Phase III includes some 1000-3000 participants to assess efficacy and safety of the drug at different doses. (wikipedia.org)
Approvals3
  • 1. Conditional approvals will be granted to provide early access to innovative drugs which address severe life-threatening diseases without any effective cures. (ropesgray.com)
  • Only innovative drugs not yet marketed in China that can treat severe illness, life-threatening diseases, or rare diseases are eligible for conditional approvals. (ropesgray.com)
  • For any new drug applications ("NDA") that may be eligible for conditional approvals, the applicant may apply for a meeting with the Center for Drug Evaluation ("CDE") to discuss the possibility of conditional approvals and relevant requirements. (ropesgray.com)
Effectiveness2
  • It can last from several months to 2 years, and it seeks to investigate the effectiveness of the drug and its side effects. (medicalnewstoday.com)
  • A diagnostic companion device is a medical device that can obtain information about the effectiveness and safety of a drug. (medicalnewstoday.com)
20231
  • MTx plans to submit an Investigational New Drug Application (IND) during the first quarter 2023 to initiate a multicenter study in the U.S. (yourerie.com)
Illness1
20201
  • March 10, 2020 - Reminder: FORMS-F Grant Application Forms & Instructions Must be Used for Due Dates On or After May 25, 2020- New Grant Application Instructions Now Available. (nih.gov)
Additionally1
  • Additionally, our study identifies cases of several newly described drugs and drug classes that have not been previously described in literature. (bvsalud.org)
Administration2
  • A generic drug is similar to the original brand name, dose, quality and route of administration. (biotechresearchgroup.com)
  • The administration of diazepam can be attempted to control seizure activity, but IV pyridoxine is the drug of choice, in a gram-for-isoniazid-ingested-gram dose. (medscape.com)
Safety4
  • The data generated from the expanded access study can be used as supportive safety data in the NDA application dossier. (ropesgray.com)
  • It aims to analyze the safety of the drug, possible side effects, and how the body metabolizes and removes it. (medicalnewstoday.com)
  • The company believes this platform will harness the cellular chaperome network, potentially improving drug safety and efficacy due to selective targeting of disease tissues. (biospace.com)
  • Nevertheless, the results generate some reason for concern that current application of traditional safety or uncertainty factor approaches may allow appreciable incidences of respons- es in some cases. (cdc.gov)
Devices1
  • These two drafts echoed the central government's recent reform to encourage innovation in drugs and medical devices. (ropesgray.com)
Study4
  • For any patient participating in the expanded access study, their physicians must evaluate and conclude that the probable risks to the patient from the investigational drug are no greater than the probable risks from the disease, and the patient must give informed consent to such compassionate use. (ropesgray.com)
  • A clinical trial in which participants are unaware of who is included in an experimental arm (given an active drug) or control arm (given the placebo) of the study. (ipmglobal.org)
  • Any investigational drugs or participation in any other clinical study for 6 weeks or 5 half life period (in case of an experimental drug, whichever is longer) prior to screening. (who.int)
  • Overall, in accordance with a separate AAM study, this delay in generic drug coverage could lead to seniors paying up to $four billion a yr out of pocket. (20mg-cheapesttadalafil.com)
Compassionate1
  • In mid-December, our medical team submitted an application to the FDA asking for permission under "compassionate use" to treat Addi and Cassi with cycolodextrin IV infusions. (addiandcassi.com)
Patient6
  • Ifosfamide is the chemotherapy drug that PharmaCyte uses with the encapsulated cells that are implanted in a patient as close to the tumor as possible. (stockmarketmediagroup.com)
  • FDA has a long history of supporting patient access to investigational new treatments. (fda.gov)
  • Today, we're lifting another potential burden for physicians who apply to FDA to use an investigational drug to treat their patient. (fda.gov)
  • 3) "Routine patient care costs" shall include coverage for reasonable and medically necessary services needed to administer the drug or device under evaluation in the clinical trial. (mo.gov)
  • Single application of estradiol coated microparticles in a topical gel applied directly to the submandibular skin (40 microlites of gel containing 0.4 micrograms of estradiol applied per patient). (who.int)
  • These abstracts reinforce the consistent clinical activity shown by our drug candidates across broad patient populations with RET-altered cancers and systemic mastocytosis. (biospace.com)
Vaccine Testing and Approval Process | CDC
Vaccine Testing and Approval Process | CDC (cdc.gov)
NYSE:COTY | Stock Discussion | Coty Inc. Class A
NYSE:COTY | Stock Discussion | Coty Inc. Class A (stockhouse.com)
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 (cdc.gov)
Use of Anthrax Vaccine in the United States
Use of Anthrax Vaccine in the United States (cdc.gov)
Overview of Lynparza: Treatment for ovarian cancer
Overview of Lynparza: Treatment for ovarian cancer (medicalnewstoday.com)
Drug Makers File With European Medicines Agency For Regulatory Approval Of Investigational Ebola Vaccine; WHO Notes Fluctuating...
Drug Makers File With European Medicines Agency For Regulatory Approval Of Investigational Ebola Vaccine; WHO Notes Fluctuating... (kff.org)
Acticor Biotech annonce ses résultats financiers semestriels 2022 et fait le point sur ses avancées cliniques
Acticor Biotech annonce ses résultats financiers semestriels 2022 et fait le point sur ses avancées cliniques (fr.finance.yahoo.com)
Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (ACIP) (cdc.gov)
Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (cdc.gov)
Zydus Cadila gets approval from DCGI for trial of novel molecule ZYIL1 | Mint
Zydus Cadila gets approval from DCGI for trial of novel molecule ZYIL1 | Mint (livemint.com)
Chickenpox Clinical Presentation: History, Physical Examination
Chickenpox Clinical Presentation: History, Physical Examination (medscape.com)
U.S. Vaccine Safety - Overview, History, and How It Works | CDC
U.S. Vaccine Safety - Overview, History, and How It Works | CDC (cdc.gov)
Cholesterol metabolism | The Addi and Cassi Fund - Niemann Pick Type C
Cholesterol metabolism | The Addi and Cassi Fund - Niemann Pick Type C (addiandcassi.com)
Summary of H.R. 307 (113th): Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 - GovTrack.us
Summary of H.R. 307 (113th): Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 - GovTrack.us (govtrack.us)
Rabies Treatment & Management: Approach Considerations, Preexposure Prophylaxis or Immunization, Postexposure Approach to...
Rabies Treatment & Management: Approach Considerations, Preexposure Prophylaxis or Immunization, Postexposure Approach to... (medscape.com)
Chickenpox: Practice Essentials, Background, Pathophysiology
Chickenpox: Practice Essentials, Background, Pathophysiology (emedicine.medscape.com)
FDAAA 801 and the Final Rule - ClinicalTrials.gov
FDAAA 801 and the Final Rule - ClinicalTrials.gov (clinicaltrials.gov)
Site Search | Florida Department of Health
Site Search | Florida Department of Health (floridahealth.gov)
Hookipa Reaches First HIV Vaccine Milestone in Deal With Gilead
Hookipa Reaches First HIV Vaccine Milestone in Deal With Gilead (labiotech.eu)
Verona Achieve Positive Top-Line Results for Phase IIa Trial of COPD Drug
Verona Achieve Positive Top-Line Results for Phase IIa Trial of COPD Drug (labiotech.eu)
Novavax COVID-19 vaccine booster gets expanded authorization
Novavax COVID-19 vaccine booster gets expanded authorization (labiotech.eu)
French collaboration to develop Oncology-targeted Therapy - Labiotech.eu
French collaboration to develop Oncology-targeted Therapy - Labiotech.eu (labiotech.eu)
Evox Therapeutics Raises €40M to Deliver Drugs to Hard-to-Reach Targets
Evox Therapeutics Raises €40M to Deliver Drugs to Hard-to-Reach Targets (labiotech.eu)
Nick Laboratory
Nick Laboratory (nationaljewish.org)
Frequently Asked Questions - Statement of Investigator (Form FDA 1572) | FDA
Frequently Asked Questions - Statement of Investigator (Form FDA 1572) | FDA (fda.gov)
H1 class=Story-Title>Progressive Vaccinia in a Military Smallpox Vaccinee --- United States,...
H1 class="Story-Title">Progressive Vaccinia in a Military Smallpox Vaccinee --- United States,... (cdc.gov)
Responding to Detection of Aerosolized Bacillus anthracis by Autonomous Detection Systems in the Workplace
Responding to Detection of Aerosolized Bacillus anthracis by Autonomous Detection Systems in the Workplace (cdc.gov)